RSC Advances



View Article Online

View Journal | View Issue

PAPER

Check for updates

Cite this: RSC Adv., 2022, 12, 34126

Received 23rd May 2022 Accepted 18th November 2022

DOI: 10.1039/d2ra03226k

rsc.li/rsc-advances

1. Introduction

The attainment of affordable and sustainable cancer therapeutics is an emerging issue for both developing and other nations.¹⁻³ Lead structures that can be realised in only a few synthetic steps, but still allow diverse structure–activity relationships to be defined are of high desirability in this area. Additionally, the use of only widely-available low-cost chemical building blocks from sustainable sources is also an enabling strategy. One such attractive fragment is the thiazole core (Scheme 1). Straightforward to prepare, their derivatives have already provided many disparate active lead compounds.^{4,5} The

Design, and synthesis of selectively anticancer 4cyanophenyl substituted thiazol-2-ylhydrazones[†]

Hasnain Mehmood,^a Mustapha Musa,^b Simon Woodward, ^b*^b Md Shahadat Hossan,^c Tracey D. Bradshaw, ^b^c Muhammad Haroon,^a Andrew Nortcliffe ^d and Tashfeen Akhtar ^b*^a

Cyclization of substituted thiosemicarbazones with α -bromo-4-cyanoacetophenone allows rapid singlestep sustainable syntheses of 4-cyanophenyl-2-hydrazinylthiazoles libraries (30 examples, 66-79%). All show anticancer efficacy against HCT-116 and MCF-7 carcinoma cell lines with the majority being more active than cisplatin positive controls. The compounds 2-(2-(2-hydroxy-3-methylbenzylidene) hydrazinyl)-4-(4-cyanophenyl)thiazole (3f) and 2-(2-((pentafluorophenyl)methylene)-hydrazinyl)-4-(4cyanophenyl)thiazole (3a') show optimal GI_{50} values (1.0 \pm 0.1 μ M and 1.7 \pm 0.3 μ M) against MCF-7 breast cancer cells. Against colorectal carcinoma HCT-116 cells, (2-(2-(3-bromothiophen-2-yl) methylene)hydrazinyl)-4-(4-cyanophenyl)thiazole (3b'), 2-(2-(2-hydroxy-3-methylbenzylidene) hydrazinyl)-4-(4-cyanophenyl) thiazole (3f), 2-(2-(2,6-dichlorobenzylidene) hydrazinyl)-4-(4-cyanophenyl) hydrazinyl) hydrazinyl hydrazinythiazole (3n) and 2-(2-(1-(4-fluorophenyl)ethylidene)hydrazinyl)-4-(4-cyanophenyl)thiazole <math>(3w) are the most active (GI₅₀ values: 1.6 \pm 0.2, 1.6 \pm 0.1, 1.1 \pm 0.5 and 1.5 \pm 0.8 μ M respectively). Control studies with MRC-5 cells indicate appreciable selectivity towards the cancer cells targeted. Significant (p < p0.005) growth inhibition and cytotoxicity effects for the thiazoles 3 were corroborated by cell count and clonogenic assays using the same cancer cell lines at 5 and 10 μ M agent concentrations. Cell cycle, caspase activation and Western blot assays demonstrated that compounds 3b' and 3f induce cancer cell death via caspase-dependent apoptosis. The combination of straight forward synthesis and high activity makes the thiazoles 3 an interesting lead for further development.

4-substituted 2-hydrazinylthiazole species (3) are attractive, as these are easily prepared from ubiquitous thiosemicarbazones (1) and low cost α -bromoketones (2) (Scheme 1). In preliminary studies, associated with another programme,⁶ we had



Scheme 1 Accessing 2-hydrazinylthiazoles (3) and initial hit discovery.

^aDepartment of Chemistry, Mirpur University of Science and Technology (MUST), 10250-Mirpur (AJK), Pakistan. E-mail: tashfeenchem@must.edu.pk

^bGSK Carbon Neutral Laboratories for Sustainable Chemistry, University of Nottingham, Triumph Road Nottingham, NG7 2TU, UK

^cSchool of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK

^dSchool of Chemistry, University of Nottingham, University Park, Nottingham NG7 2RD, UK

[†] Electronic supplementary information (ESI) available: ¹H and ¹³C NMR spectra of prepared compounds and supporting biological information. See DOI: https://doi.org/10.1039/d2ra03226k



Fig. 1 Optimal literature⁸⁻¹² cytotoxic activities for 2-hydrazinylthiazoles (3), and one closely related compound, compared to the present work. Notes: ^atime period not given; ^bmouse model, all other cell lines are human derived.

incorporated 2-hydrazinylthiazole units into the ligand (4). To our surprise the exemplar with a 4-cyanophenyl group (alone in the series) showed very high activity against the HCT-116 human colon cancer cell line, while all others had GI_{50} values > 100 μ M (Scheme 1).

The ~2 μ M activity of the 4-cyanophenyl derivative of 4 is unusual. The anti-cancer activities of 2-hydrazinylthiazoles (3) are normally quite modest (see Fig. 1). In 2014 Secci and coworkers proposed that pharmacophores of type 3 are histone acetyltransferase (HAT) inhibitors that facilitate the onset of apoptosis in HCT-116.^{7,8}

The Secci study activities are low (only 10% apoptosis at 100 μM).^{7,8} However, in the subsequent 8 years a significant range of additional thiazole derivatives (ca. 80 compounds) have been prepared by various groups, the most active of which are summarised in Fig. 1.9-13 Although some improved activities are present in this global library, over the original Secci lead, the most active compounds are still at best only equipotent to cisplatin and related positive controls. We noticed from both thiazole and related literature that incorporation of cyano functionality onto thiazole and other heterocycles, in many cases, enhances anticancer potency.14-16 Although the compounds 4 suggest a clear (anti-cancer) benefit from 4-cyanophenyl inclusion within the 2-hydrazinylthiazole derivative 4, this series was synthetically problematic to work with. Therefore, as part of our ongoing research,17 we set out to synthesise a range of more simply and easily accessed 2-hydrazinylthiazole species (3), all bearing a cyanoaryl moiety at position R^1 (Scheme 1), to confirm the generality of the apparent activity effect detected.

2. Experimental

2.1. General

All reagents used in synthesis and biological evaluation were commercial (Merck, Fischer and Acros Organics) and were used as supplied. Initial thiosemicarbazones (1) are readily available either commercially and via simple one-step literature procedures (see ref. 17-25). Chromatographic silica gel 60 (220-240 mesh) was obtained from Merck. Thin layer chromatography was performed on foil-backed plates coated with Merck Silica gel 60 F254. Plates were developed using ultraviolet light and basic aqueous potassium permanganate. Uncorrected melting points were measured on a DMP-300 A&E Lab apparatus. Ultraviolet (UV) absorption spectra were recorded on Shimadzu Ultraviolet-1800 spectrophotometer in the range 200-800 nm. Infrared spectra were recorded on a Bruker OPUS FT-IR spectrometer by attenuated total reflection (diamond-ATR) on solid films. Proton and ¹³C NMR spectra were recorded on Bruker DPX-400 and 500 MHz spectrometers at ambient temperatures; where necessary HSQC and HMBC techniques were used to confirm structural connectivities. Mass spectra were recorded on Bruker Micro TOF-ESI positive targeted mode. Elemental (CHN) analyses were conducted on a CE-440 Elemental Analyzer.

2.2. Synthesis of 2-(2-benzylidenehydrazinyl)-4-(4cyanophenyl) thiazoles (3a–d')

Syntheses of (3a-d') were achieved by refluxing equimolar mixtures of the required thiosemicarbazone (1) (1.00 mmol) and α -bromo-4-cyanoacetophenone (1.00 mmol) in absolute ethanol (20 mL) for 3 to 3.5 hours. The progress of reaction was

monitored by TLC using acetone/*n*-hexane (1:3), if necessary, reflux times were extended to 5 h; the R_f values for individual compounds are given below. On completion the reaction mixture was allowed to cool to room temperature and poured on crushed ice (*ca.* 20 g). The precipitated solids were filtered off, washed with copious water and dried under vacuum to afford **3a–d'**. Spectral data as described below. Purity estimates are based on expected %*C* values from elemental analyses.

2.2.1 2-(2-(2-Fluorobenzylidene)hydrazinyl)-4-(4-

cyanophenyl) thiazole (3a). Off-yellow solid (69% yield), mp 230–232 °C, $R_{\rm f}$ 0.43 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 339 nm, IR (ATR) *v*_{max} 3257 (N−H), 3116 (C−H), 2218 (C≡N), 1606 (thiazole), 1562 (C=N), 1487, 1435, 1357, 1330 (C=C), 1053-717 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.14 (s, 1H, HC=N), 7.97-7.89 (m, 3H, ArH), 7.73 (d, *J* = 8.3 Hz, 2H, ArH), 7.41 (d, J = 6.7 Hz, 1H, ArH), 7.23 (app. t, J = 7.7 Hz, 1H, ArH), 7.12 (app. t, J = 9.3 Hz, 1H, ArH), 7.05 (s, 1H, thiazole-H), ¹³C NMR (100 MHz, CDCl₃) δ 168.9 (thiazole C2), 161.4 (d, ${}^{1}J_{CF} = 216.8 \text{ Hz}, \text{Ar}_{\text{ipso}}$, 146.3 (thiazole C4), 138.5 (C=N), 136.2, 132.9, 132.1, 126.7, 126.4, 124.6, 121.1 (Ar), 118.6 (CN), 116.0 (d, ${}^{2}J_{CF} = 20.9$ Hz, Ar), 112.1 (Ar_{ipso}), 106.1 (thiazole C5), not all signals could be observed due to J_{CF} couplings and low compound solubility, ¹⁹F NMR (375 MHz, $CDCl_3$) δ -120.03, HRMS m/z 323.0757 $[M + H]^+$ calcd for C₁₇H₁₁FN₄S: 323.0766. Anal. for 3a, as isolated, C17H11FN4S: C, 66.34; H, 3.44; N, 17.38. Found: C, 67.39; H, 3.70; N, 17.43, corresponding to 98% purity.

2.2.2 2-(2-(3-Fluorobenzylidene)hydrazinyl)-4-(4-

cyanophenyl) thiazole (3b). Yellow solid (79% yield), mp 177-178 °C, R_f 0.44 (acetone/*n*-hexane, 1:3), λ_{max} 337 nm, IR (ATR) v_{max} 3278 (N-H), 3126 (C-H) 2218 (C≡N), 1606 (thiazole), 1573 (C=N), 1487, 1415, 1355, 1257 (C=C), 1051-717 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 12.38 (s, 1H, NH), 8.05 (d, J = 2.5 Hz, 2H, ArH), 8.02 (s, 1H, HC=N), 7.86 (d, J = 8.5 Hz, 2H, ArH), 7.65 (s, 1H, thiazole-H), 7.52-7.42 (m, 3H, ArH), 7.21 (app. tt, J = 9.2, 2.5 Hz, 1H, ArH), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.9 (thiazole C2), 162.9 (d, ${}^{1}J_{CF} = 243.6$ Hz, Ar_{ipso}), 149.4 (thiazole C4), 140.6, 139.2 (C=N), 137.3 (d, ${}^{3}J_{CF} = 8.1$ Hz, Ar), 133.2, 131.3 (d, ${}^{3}J_{CF} = 8.4$ Hz, Ar), 126.6, 123.1 (d, ${}^{4}J_{CF} =$ 2.9 Hz, Ar), 119.5 (CN), 116.5 (d, ${}^{2}J_{CF} = 21.6$ Hz, Ar), 112.7 (d, ${}^{2}J_{CF}$ = 22.7 Hz, Ar), 110.1 (Ar_{ipso}), 108.3 (thiazole C5), ¹⁹F NMR (375) MHz, DMSO-d₆) δ –112.80 (s, 1F), HRMS *m*/*z* 323.0759 [M + H]⁺ calcd for C17H11FN4S: 323.0766. Anal. for 3b, as isolated, C₁₇H₁₁FN₄S: C, 63.34; H, 3.44; N, 17.38; found: C, 67.44; H, 3.59; N, 17.51%, corresponding to 95% purity.

2.2.3 2-(2-(1-(3-Bromophenyl)ethylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3c). Off-white solid (70% yield), mp 224– 226 °C, R_f 0.56 (acetone/*n*-hexane, 1 : 3), $\lambda_{max} = 336$ nm, IR (ATR) ν_{max} 3305 (N–H), 3061, 2927 (C–H), 2223 (C \equiv N), 1604–1421 (thiazole), 1558 (C=N), 1479, 1342, 1280, 1261 (C=C), 1053– 727 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, CDCl₃) δ 7.94 (app d, J = 5.0 Hz, 2H, ArH), 7.91 (s, 1H, Ar–H), 7.72 (app d, J = 4.6 Hz, 2H, ArH), 7.69 (s, 1H, thiazole-H) 7.53 (d, J =7.9 Hz, 1H, ArH), 7.31 (d, 1H, Ar–H, J = 7.9 Hz), 7.10 (s, 1H, ArH), 2.29 (s, 3H, CH₃), ¹³C NMR (100 MHz, CDCl₃) δ 169.1 (thiazole C2), 149.2 (thiazole C4), 139.4 (HC=N), 138.5, 132.6, 132.1, 130.0, 129.0, 126.3, 124.5, 122.8 (Ar), 118.9 (CN), 111.1 (Ar_{ipso}), 107.2 (thiazole C5), 12.9 (CH₃), HRMS *m*/z 397.0117 [M + H]⁺ calcd for C₁₈H₁₃BrN₄S 397.0122. Anal. for **3c**, as isolated, calcd for C₁₈H₁₃BrN₄S: C, 54.42; H, 3.30; N, 14.10. Found: C, 54.23; H, 3.07; N, 13.92%, corresponding to >99% purity.

2.2.4 2-(2-(3-Iodobenzylidene)hydrazinyl)-4-(4-

cyanophenyl) thiazole (3d). Off-yellow solid (67% yield), mp 197–198 °C, $R_{\rm f}$ 0.41 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 341 nm, IR (ATR) ν_{max} 3259 (N-H) overlapped by br 3600-2600 (N-HBr) 3041 (C-H), 2221 (C=N), 1618 (thiazole), 1566 (C=N), 1494, 1415, 1359, 1265 (C=C), 1051-680 (characteristic of thiazole) cm⁻¹, ¹H NMR (500 MHz, DMSO-d₆) δ 12.36 (s, 1H, NH), 8.03 (d, J = 8.5 Hz, 2H, Ar-H), 8.00 (s, 1H, HC=N), 7.99 (s, 1H, ArH), 7.86 (d, J = 8.5 Hz, 2H, ArH), 7.72 (d, J = 8.0 Hz, 1H, ArH), 7.66 (d, J = 8.0 Hz, 1H, ArH), 7.65 (s, 1H, thiazole-H), 7.22 (app. t, J = 8.0 Hz, 1H, ArH), ¹³C NMR (125 MHz, DMSO-d₆) δ 168.8 (thiazole C2), 149.3 (thiazole C4), 140.4, 139.1 (C=N), 138.2, 137.1, 134.9, 133.2, 131.4, 128.9, 126.6, 126.1 (Ar_{ipso}), 119.5 (CN), 110.1 (Ar_{ipso}), 108.3 (thiazole C5), HRMS m/z 430.9841 $[M + H]^+$ calcd for $C_{17}H_{11}IN_4S$: 430.9827. Anal. for 3d · 1/10HBr, as isolated, C₁₇H_{11,1}Br_{0.1}IN₄S: C, 46.58; H, 2.55; N, 12.78. Found: C, 46.43; H, 2.39; N, 12.74, corresponding to >99% for this salt.

2.2.5 2-(2-(1-(4-Fluorophenyl)ethylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3e). Off-yellow solid (76% yield), mp 267–269 °C, $R_{\rm f}$ 0.62 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 332 nm, IR (ATR) *v*_{max} 3348 (N−H), 3116, 3041 (C−H), 2220 (C≡N), 1606-1408 (thiazole), 1558 (C=N), 1508, 1346, 1280, 1213 (C=C), 1053-702 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 11.35 (s, 1H, NH), 8.06 (d, J = 8.5 Hz, 2H, ArH), 7.87 (d, J = 8.5 Hz, 2H, Ar-H), 7.82 (dd, J = 9.0, 5.5 Hz, 2H, ArH), 7.65 (s, 1H, thiazole-H), 7.26 (app t, J = 9.0 Hz, 2H, ArH), 2.33 (s, 3H, CH₃), ¹³C NMR (100 MHz, DMSO-d₆) δ 170.6 (thiazole C2), 163.0 (d, ${}^{1}J_{CF} = 246.1 \text{ Ar}_{ipso}$), 149.5 (thiazole C4), 146.4, 139.4 (imine C=N), 134.8 (d, ${}^{4}J_{CF} = 2.9$ Hz, Ar), 133.2, 128.3 (d, ${}^{3}J_{CF} = 8.4$ Hz, Ar), 126.6 (Ar), 119.5 (CN), 115.9 (d, ${}^{2}J_{CF} = 21.6$ Hz, Ar), 110.0 (Ar_{inso}), 108.5 (thiazole C5), 14.6 (CH₃), ¹⁹F NMR (375 MHz, DMSO-d₆) δ -113.09, HRMS m/z 337.0922 [M + H]⁺ calcd for C18H13FN4S 337.0923. Anal. for 3e, as isolated, calcd for C₁₈H₁₃FN₄S: C, 65.27; H, 3.90; N, 16.66. Found: C, 67.67; H, 3.97; N, 16.86%, corresponding to >99% purity.

2.2.6 2-(2-(2-Hydroxy-3-methylbenzylidene) hydrazinyl)-4-(4-cyanophenyl) thiazole (3f). Light orange solid (73% yield) mp 273–275 °C; $R_f 0.34$ (acetone/*n*-hexane, 1:3), $\lambda_{max} 352$ nm, IR (ATR) v_{max} 3298 (N-H), 3163 (O-H), 3165, 3041 (C-H), 2216 (C≡N), 1604-1431 (thiazole), 1573 (C=N), 1483, 1357, 1249, 1147 (C=C), 1083 (C-O), 1051-702 (characteristic of thiazole) cm⁻¹, ¹H NMR (500 MHz, DMSO-d₆) δ 12.38 (s, 1H, NH), 10.28 (s, 1H, OH), 8.30 (s, 1H, HC=N), 8.04 (d, *J* = 8.5 Hz, 2H, ArH), 7.87 (d, J = 8.5 Hz, 2H, ArH), 7.67 (s, 1H, thiazole-H), 7.30 (d, *J* = 7.8 Hz, 1H, ArH), 7.18 (d, *J* = 7.1 Hz, 1H, ArH), 6.85 (app t, J = 7.5 Hz, 1H, ArH), 2.23 (s, 3H, CH₃), ¹³C NMR (125 MHz, DMSO-d₆) δ 167.9 (thiazole C2), 155.1 (Ar_{ipso}), 149.6 (thiazole C4), 144.9, 139.0 (C=N), 133.2, 132.4, 127.8, 126.7, 125.5, 119.9, 119.4 (Ar), 118.6 (CN), 110.3 (Ar_{ipso}), 107.7 (thiazole C5), 16.1 (CH₃), HRMS m/z 335.0958 [M + H]⁺ calcd for C18H14N4OS: 335.0966. Anal. for 3f, as isolated, calcd for C18H14N4OS: C, 64.65; H, 4.22; N, 16.75. Found: C, 64.18; H, 4.21; N, 16.55%, corresponding to >99% purity.

2-(2-(5-Chloro-2-hydroxybenzylidene) hydrazinyl)-4-2.2.7 (4-cyanophenyl) thiazole (3g). Off-white solid (78% yield), mp 277-278 °C, R_f 0.33 (acetone/n-hexane, 1:3), λ_{max} 344 nm, IR (ATR) *v*_{max} 3211 (O−H), 3192 (C−H), 3109 (N−H), 2229 (C≡N), 1608 (thiazole), 1575 (C=N), 1479, 1382, 1327, 1288 (C=C), 1182 (C-O), 1056-740 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 12.26 (br s, 1H, OH), 10.34 (br s, 1H, NH), 8.29 (s, 1H, HC=N), 8.03 (d, I = 8.5 Hz, 2H, ArH), 7.86 (d, I =8.5 Hz, 2H, ArH), 7.63 (s, 1H, thiazole-H), 7.62 (d, J = 2.8 Hz, 1H, ArH), 7.24 (dd, J = 8.7, 2.8 Hz, 1H, ArH), 6.93 (d, J = 8.7 Hz, 1H, ArH), 13 C NMR (100 MHz, DMSO-d₆) δ 168.7 (thiazole C2), 155.1 (Ar_{ipso}), 149.2 (thiazole C4), 139.1 (C=N), 138.0, 133.2, 130.4, 126.6, 125.1, 123.7, 122.6 (Ar), 119.4 (CN), 118.4 (Ar), 110.1 (Ar_{ipso}) , 108.0 (thiazole C5), HRMS m/z 355.0428 $[M + H]^+$ calcd for $C_{17}H_{11}ClN_4OS$: 355.0420. Anal. for $3g \cdot 1/3H_2O$, as isolated, C₁₇H_{11.66}N₄O_{1.33}S: C, 56.60; H, 3.26; N, 15.53. Found: C, 57.04; H, 2.93; N, 15.18%, corresponding to 99% purity for solvate.

2.2.8 2-(2-(5-Bromo-2-hydroxybenzylidene) hydrazinyl)-4-(4-cyanophenyl) thiazole (3h). Off-white solid (70% yield), mp 274–275 °C, $R_{\rm f}$ 0.32 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 352 nm, IR (ATR) v_{max} 3286 (br, O-H), 3115 (N-H), 3115 (C-H stretching), 2214 (C=N), 1604 (thiazole), 1581 (C=N), 1473, 1377, 1282, 1180 (C=C), 1155 (C-O), 1053-698 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 12.31 (s, 1H, NH), 10.38 (s, 1H, OH), 8.28 (s, 1H, HC=N), 8.04 (d, J = 8.4 Hz, 2H, ArH), 7.87 (d, J = 8.4 Hz, 2H, ArH), 7.76 (d, J = 2.6 Hz, 1H, ArH), 7.65 (s, 1H, thiazole-H), 7.36 (dd, *J* = 8.8, 2.6 Hz, 1H, ArH), 6.88 (d, J = 8.8 Hz, 1H, ArH), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.7 (thiazole C2), 155.5 (Ar_{ipso}), 149.4 (thiazole C4), 139.2 (C=N), 137.7, 133.2, 133.2, 127.9, 126.6, 123.2, 119.5 (Ar), 118.9 (CN), 111.3 (Ar_{ipso}), 110.1 (Ar_{ipso}), 108.1 (thiazole C5), HRMS *m*/*z* 398.9903 $[M + H]^+$ calcd for C₁₇H₁₁BrN₄OS: 398.9915. Anal. for 3p, as isolated, calcd for C₁₇H₁₁BrN₄OS: C, 51.14; H, 2.78; N, 14.03. Found: C, 51.03; H, 2.65; N, 13.73%, corresponding to >99% purity.

2.2.9 2-(2-(2,5-Dimethylbenzylidene)hydrazinyl)-4-(4-

cyanophenyl) thiazole (3i). Off-yellow solid (75% yield) mp 187– 188 °C, *R*_f 0.54 (acetone/*n*-hexane, 1:3), λ_{max} 349 nm, IR (ATR) ν_{max} 3302 (N–H), 2949 (C–H), 2233 (C=N), 1604–1384 (thiazole), 1575 (C=N), 1481, 1348, 1271, 1204 (C=C), 1049–700 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, *J* = 8.4 Hz, 2H, ArH), 7.72 (s, 1H, thiazole-H), 7.69 (d, 2H, *J* = 8.4 Hz, ArH), 7.32 (s, 1H, HC=N), 7.09 (s, 1H, ArH), 7.09–7.01 (m, 2H, ArH), 2.36 (s, 3H, CH₃), 2.12 (s, 3H, CH₃), ¹³C NMR (100 MHz, CDCl₃) δ 170.3 (thiazole C2), 148.9 (thiazole C4), 142.4, 138.5 (C=N), 135.7, 133.6, 132.7, 131.2, 131.0, 130.5, 127.5, 126.4 (Ar), 118.8 (CN), 111.2 (Ar_{ipso}), 106.8 (thiazole C5), 20.9 (CH₃), 19.3 (CH₃), HRMS *m*/*z* 333.1167 [M + Na]⁺ calcd for C₁₉H₁₆N₄S: 333.1174, Anal. for **3i**, as isolated, calcd for C₁₉H₁₆N₄S: C, 68.65; H, 4.85; N, 16.85. Found: C, 68.54; H, 4.61; N, 16.69%, corresponding to >99% purity.

2.2.10 2-(2-(2,5-Dimethoxybenzylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3j). Beige solid (72% yield), mp 158– 159 °C, R_f 0.52 (acetone/*n*-hexane, 1:3), λ_{max} 347 nm, IR (ATR) ν_{max} 3263 (N–H), 3109, 2953 (C–H), 3100–2600 br (N–HBr salt and C–H overlapped), 2221 (C=N), 1604–1427 (thiazole), 1564 (C=N), 1496, 1278 (C=C), 1083 (C–O), 1051–702 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 8.34 (s, 1H, HC=N), 8.03 (d, *J* = 8.4 Hz, 2H, ArH), 7.86 (d, *J* = 8.4 Hz, 2H, ArH), 7.63 (s, 1H, thiazole-H), 7.31 (d, *J* = 3.1 Hz, 1H, ArH), 7.03 (d, *J* = 9.0 Hz, 1H, ArH), 6.96 (dd, *J* = 9.0, 3.1 Hz, 1H, ArH), 3.80 (s, 3H, OCH₃), 3.76 (s, 3H, OCH₃), ¹³C NMR (100 MHz, DMSO-d₆) δ 169.0 (thiazole C2), 153.7 (Ar_{ipso}), 152.1 (Ar_{ipso}), 149.3 (thiazole C4), 139.2 (C=N), 137.4, 133.1, 126.6, 123.4 (Ar), 119.5 (CN), 116.7, 113.7, 110.0 (Ar), 109.8 (Ar_{ipso}), 108.0 (thiazole C5), 56.6 (CH₃), 55.8 (CH₃), HRMS *m*/*z* 365.1058 [M + H]⁺ calcd for C₁₉H_{16.25}Br_{0.25}N₄O₂S: C, 59.33; H, 4.26; N, 14.57. Found: C, 59.54; H, 4.32; N, 14.16%, corresponding to >99% purity for this salt.

2.2.11 2-(2-(4-Methoxy-2-methylbenzylidene) hydrazinyl)-4-(4-cyanophenyl) thiazole (3k). Beige solid (65% yield), mp 240–242 °C, R_f 0.51 (acetone/*n*-hexane, 1:3), λ_{max} 343 nm, IR (ATR) $\nu_{\rm max}$ 3269 (N–H), 3120, 2918 (C–H), 2223 (C=N), 1606 (thiazole), 1566 (C=N), 1504, 1448, 1411, 1359 (C=C), 1170 (C-O), 1051–709 (characteristic of thiazole vibrations), ¹H NMR (500 MHz, DMSO-d₆) δ 12.04 (s, 1H, NH), 8.23 (s, 1H, HC=N), 8.03 (d, J = 8.6 Hz, 2H, ArH), 7.86 (d, J = 8.6 Hz, 2H, ArH), 7.64 (d, J = 8.5 Hz, 1H, ArH), 7.59 (s, 1H, thiazole-H), 6.88–6.80 (m, 2H, ArH), 3.78 (s, 3H, OCH₃), 2.43 (s, 3H, CH₃), ¹³C NMR (125 MHz, DMSO-d₆) δ 169.2 (thiazole C2), 160.3 (Ar_{ipso}), 149.3 (thiazole C4), 141.6, 139.3 (C=N), 138.4, 133.1, 128.5, 126.6, 125.4, 119.4 (CN), 116.5 (Ar), 112.6 (Ar_{ipso}), 109.9 (Ar), 107.7 (thiazole C5), 55.6 (OCH₃), 20.4 (CH₃), HRMS m/z 349.1119 [M + H⁺ calcd for C₁₉H₁₆N₄OS: 349.1123. Anal. for 3k, as isolated, calcd for C19H16N4OS: C, 65.50; H, 4.63; N, 16.08. Found: C, 65.51; H, 4.56; N, 16.14%, corresponding to >99% purity.

2.2.12 2-(2-(2,4-Dimethoxybenzylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (31). Brick red solid (71% yield), mp 237-238 °C, $R_{\rm f}$ 0.53 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 345 nm, IR (ATR) *v*_{max} 3277 (N-H), 2972 (C-H), 2223 (C≡N), 1598 (thiazole), 1568 (C=N), 1471, 1452, 1354, 1276 (C=C), 1168 (C-O), 1051-707 (characteristic of thiazole) cm⁻¹, ¹H NMR (500 MHz, DMSO-d₆) δ 12.03 (s, 1H, NH), 8.29 (s, 1H, HC=N), 8.03 (d, J = 8.6 Hz, 2H, ArH), 7.86 (d, J = 8.6 Hz, 2H, ArH), 7.71 (d, J = 9.3 Hz, 1H, ArH), 7.59 (s, 1H, thiazole-H), 6.65-6.60 (m, 2H, ArH), 3.85 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃), ¹³C NMR (125 MHz, DMSO-d₆) δ 169.1 (thiazole C2), 162.4 (Ar_{ipso}), 158.9 (Ar_{ipso}), 149.3 (thiazole C4), 139.3 (C=N), 137.9, 133.1, 126.6, 126.5 (Ar), 119.5 (CN), 115.6, 109.9 (Ar_{ipso}), 107.6 (thiazole C5), 106.9 (Ar), 98.7 (Ar), 56.2 (CH₃), 55.9 (CH₃), HRMS m/z 365.1062, $[M + Na]^+$ calcd for C19H16N4O2S: 365.1072. Anal. for 3l, as isolated, calcd for C19H16N4O2S: C, 62.62; H, 4.43; N, 15.37. Found: C, 62.27; H,4.29; N, 15.09%, corresponding to >99% purity.

2.2.13 2-(2-(2,4-Bis-(trifluoromethyl) benzylidene) hydrazinyl)-4-(4-cyanophenyl) thiazole (3m). Off-yellow solid (66% yield), mp 253–255 °C, R_f 0.55 (acetone/*n*-hexane, 1 : 3), λ_{max} 335 nm, IR (ATR) ν_{max} 3317 (N–H), 3101 (C–H), 2218 (C≡N), 1504 (thiazole), 1562 (C=N), 1344, 1269 (C=C), 1083– 742 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSOd₆) δ 12.78 (s, 1H, NH), 8.37 (d, *J* = 2.3 Hz, 1H, HC=N), 8.29 (d, 1H, *J* = 8.5 Hz, ArH), 8.09 (d, *J* = 8.5 Hz, 1H, ArH), 8.03 (s, 1H, ArH), 8.01 (d, *J* = 8.5 Hz, 2H, ArH), 7.85 (d, *J* = 8.5 Hz, 2H, Ar-H),

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

View Article Online
Paper

7.72 (s, 1H, thiazole-H), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.2 (thiazole C2), 149.4 (thiazole C4), 138.9 (C=N), 136.7, 135.2, 133.2, 132.8, 130.0, 128.8, 127.7, 126.6, 125.2 (Ar_{ipso}), 123.6, 122.5, 119.4 (CN), 110.2 (Ar_{ipso}), 109.1 (thiazole C5); not all signals could be observed due to multiple J_{CF} couplings and low compound solubility, ¹⁹F NMR (375 MHz, DMSO-d₆) δ –57.77 (s, 3F), -61.44 (s, 3F), HRMS m/z 441.0606 [M + H]⁺ calcd for C₁₉H₁₀F₆N₄S 441.0608. Anal. for **3h** · 1/2EtOH, as isolated, calcd for C_{20.33}H₁₄F₆Cl₂N₄O_{0.66}S: C, 51.84; H, 2.83; N, 12.09. Found: C, 51.60; H, 2.00; N, 11.46%, corresponding to >99% purity for this solvate. The residual solvent was easily removed under prolonged drying.

2.2.14 2-(2-(2,6-Dichlorobenzylidene)hydrazinyl)-4-(4-

cyanophenyl) thiazole (3n). Off yellow solid (68% yield), mp 250–251 °C, *R*_f 0.45 (acetone/*n*-hexane, 1:3), λ_{max} 331 nm, IR (ATR) ν_{max} 3278 (N–H), 3115 (C–H), 2216 (C=N), 1604–1408 (thiazole), 1581 (C=N), 1562, 1483, 1433, 1361 (C=C), 1051–705 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 12.53 (s, 1H, NH), 8.29 (s, 1H, HC=N), 8.03 (d, *J* = 8.5 Hz, 2H, ArH), 7.87 (d, *J* = 8.5 Hz, 2H, ArH), 7.65 (s, 1H, thiazole-H), 7.55 (d, *J* = 8.2 Hz, 2H, ArH), 7.39 (app. t, *J* = 7.5 Hz, 1H, ArH), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.8 (thiazole C2), 149.4 (thiazole C4), 139.1 (C=N), 136.8 (Ar), 134.0 (Ar_{ipso}), 133.2, 130.9, 130.0, 129.9, 126.6 (Ar), 119.5 (CN), 110.1 (Ar_{ipso}), 108.6 (thiazole C5), HRMS *m*/*z* 373.0072 [M + Na]⁺ calcd for C₁₇H₁₀Cl₂N₄S 373.0081, Anal. for **3n**, as isolated, calcd for C₁₇H₁₀Cl₂N₄S: C, 54.70; H, 2.70; N, 15.01. Found: C, 54.56; H, 2.59; N, 14.76%, corresponding to >99% purity.

2.2.15 2-(2-(3,5-Dimethoxybenzylidene)hydrazinyl)-4-(4-

cyanophenyl) thiazole (30). Off-yellow solid (75% yield), mp 235–237 °C, $R_{\rm f}$ 0.50 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 335 nm, IR (ATR) v_{max} 3304 (N-H), 3113, 2939 (C-H) overlapped by br (O-H), 2216 (C=N), 1573 (thiazole), 1463 (C=N), 1361, 1298 (C= C), 1051–702 (characteristic of thiazole) cm⁻¹, ¹H NMR (500 MHz, DMSO-d₆) δ 12.29 (s, 1H, NH), 8.04 (d, J = 8.6 Hz, 2H, ArH), 7.98 (s, 1H, HC=N), 7.87 (d, J = 8.6 Hz, 2H, ArH), 7.65 (s, 1H, thiazole-H), 6.83 (d, J = 2.3 Hz, 2H, ArH), 6.53 (t, J = 2.3 Hz, 1H, ArH), 3.79 (s, 6H, OCH₃), ¹³C NMR (125 MHz, DMSO-d₆) δ 168.9 (thiazole C2), 161.2 (Ar_{ipso}), 149.4 (thiazole C4), 141.9, 139.2 (C=N), 136.7, 133.2, 126.6 (Ar), 119.5 (CN), 110.1 (Ar_{ipso}), 108.2 (thiazole C5), 104.7 (Ar), 101.9 (Ar), 55.7 (CH₃), HRMS m/z $365.1062 \left[M + Na\right]^+$ calcd for $C_{19}H_{16}N_4O_2S$: 365.1072. Anal. for 30·1/2H₂O, as isolated, C₁₉H_{16.25}Br_{0.25}N₄O₂S: C, 59.33; H, 4.26; N, 14.57. Found: C, 59.54; H, 4.32; N, 14.16%, corresponding to >99% purity for this solvate.

2.2.16 2-(2-(3-Bromo-5-fluorobenzylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3p). Off-yellow solid (70% yield), mp 246–247 °C, R_f 0.44 (acetone/*n*-hexane, 1:3), λ_{max} 342 nm, IR (ATR) ν_{max} 3300–2600 br (N–H and N–HBr), 3076 (C–H), 2225 (C=N), 1629 (thiazole), 1595 (C=N), 1568, 1494, 1400, 1265 (C=C), 1053–756 (characteristic of thiazole) cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ 8.03 (s, 1H, HC=N), 8.02 (d, J = 8.5 Hz, 2H, ArH), 7.86 (d, J = 8.5 Hz, 2H, ArH), 7.68 (app. s, 2H, thiazole and ArH), 7.50 (app. dd, J = 16.6, 9.0 Hz, 2H, ArH), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.7 (thiazole C2), 164.8 (d, ¹ J_{CF} = 248.3 Hz, Ar_{ipso}), 149.3 (thiazole C4), 139.0 (d, ³ J_{CF} = 8.8 Hz, Ar), 133.2 (C=N), 132.8, 128.8, 126.6 (Ar), 125.5 (d, ⁴ J_{CF} = 2.9 Hz, Ar), 122.9 (d, ${}^{3}J_{\rm CF} = 10.6$ Hz, Ar), 119.6 (CN), 119.4 (d, ${}^{4}J_{\rm CF} = 5.1$ Hz, Ar) 112.3 (d, ${}^{2}J_{\rm CF} = 23.1$ Hz, Ar), 110.1 (Ar_{ipso}), 108.6 (thiazole C5), 19 F NMR (375 MHz, DMSO-d₆) δ –110.20 (s, F), HRMS *m*/*z* 400.9866 [M + H]⁺ calcd for C₁₇H₁₀BrFN₄S: 400.9872. Anal. for **3p**·1/6HBr, as isolated, calcd for C₁₇H_{10.16}Br_{1.16}FN₄S: C, 49.24; H, 2.47; Br, 22.47; N, 13.51. Found: C, 49.57; H, 2.27; N, 13.10%, corresponding to 99% purity for this salt.

2.2.17 2-(2-(3-Fluoro-5-(trifluoromethyl)benzylidene)

hydrazinyl)-4-(4-cyanophenyl) thiazole (3q). Off-yellow solid (78% yield), mp 233-235 °C, R_f 0.52 (acetone/n-hexane, 1:3), λ_{max} 342 nm, IR (ATR) ν_{max} 3286 (N–H), 3138 (C–H) 2218 (C \equiv N), 1604 (thiazole), 1558 (C=N), 1471, 1450, 1367, 1340 (C=C), 1055–705 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 12.59 (s, 1H, NH), 8.11 (s, 1H, HC=N), 8.03 (d, J =8.3 Hz, 2H, ArH), 7.86 (m, 3H, ArH), 7.77 (d, *J* = 9.7 Hz, 1H, ArH), 7.69 (s, 1H, thiazole-H), 7.66 (d, J = 8.7 Hz, 1H, ArH), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.7 (thiazole C2), 162.8 (d, ${}^{1}J_{CF} =$ 246.1 Hz, Ar_{ipso}), 149.4 (thiazole C4), 139.3–138.4 (m, –CF₃), 133.2, 126.6, 124.9, 122.3 (CN), 119.3 (d, ${}^{3}J_{CF} = 10.6$ Hz, Ar), 116.8 (d, ${}^{2}J_{CF} = 22.7$ Hz, Ar), 113.4 (d, ${}^{2}J_{CF} = 28.2$ Hz, Ar), 110.1 (Ar_{ipso}), 108.7 (thiazole C5), ¹⁹F NMR (375 MHz, DMSO-d₆) δ (ppm) -61.48 (s, 1F, CF), -110.14 (s, 3F, CF₃), HRMS m/z391.0637 $[M + H]^+$ calcd for $C_{18}H_{10}F_4N_4S$: 391.0640. Anal. for 3q, as isolated, calcd for C₁₈H₁₀F₄N₄S: C, 55.38; H, 2.58; N, 14.35. Found: C, 57.33; H, 2.56; N, 14.62%, corresponding to 97% purity.

2.2.18 2-(2-(3-Bromo-5-nitrobenzylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3r). Yellow solid (71% yield), mp 276-278 °C, $R_{\rm f}$ 0.42 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 335 nm, IR (ATR) v_{max} 3284 (N-H), 3089 (C-H), 2214 (C≡N), 1604 (thiazole), 1556 (C=N), 1525 (N=O), 1404 (C=C), 1342 (N=O), 1286 (C=C), 1053-731 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 12.67 (s, 1H, NH), 8.46 (s, 1H, ArH), 8.32 (s, 1H, ArH), 8.25 (s, 1H, ArH), 8.13 (s, 1H, HC=N), 8.04 (d, J = 8.4 Hz, 2H, ArH), 7.87 (d, J = 8.4 Hz, 2H, ArH), 7.71 (s, 1H, thiazole-H), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.5 (thiazole C2), 149.5 (thiazole C4, Ar_{ipso} overlap), 139.1 (HC=N), 138.5, 138.2, 135.0, 133.2, 126.6, 126.2, 122.9 (Ar), 119.8 (CN), 110.2 (Ar_{ipso}), 108.8 (thiazole C5), HRMS m/z 427.9817 $[M + H]^+$ calcd for $C_{17}H_{10}^-$ BrN₅O₂S: 427.9817. Anal. for 3r, as isolated, C₁₇H₁₀BrN₅O₂S: C, 47.68; H, 2.35; N, 16.35. Found: C, 47.41; H, 2.15; N, 16.14%, corresponding to 99% purity.

2.2.19 2-(2-(3-Ethoxy-4-hydroxybenzylidene) hydrazinyl)-4-(4-cyanophenyl) thiazole (3s). Brick red solid (76% yield), mp 223–225 °C, R_f 0.36 (acetone/*n*-hexane, 1:3), λ_{max} 339 nm, IR (ATR) 3338 ν_{max} (O–H), 3290 (N–H), 3122, 2991 (C–H), 2231 (C=N), 1606 (thiazole), 1570 (C=N), 1516, 1408, 1352, 1267 (C=C), 1174 (C–O), 1047–711 (characteristic of thiazole) cm⁻¹, ¹H NMR (500 MHz, DMSO-d₆) δ 12.04 (s, 1H, NH), 8.03 (d, J = 8.5 Hz, 2H, ArH), 7.95 (s, 1H, HC=N), 7.86 (d, J = 8.5 Hz, 2H, ArH), 7.59 (s, 1H, thiazole-H), 7.22 (d, J = 2.0 Hz, 1H, ArH), 7.08 (dd, 1H, Ar–H, J = 8.2, 2.0 Hz, 1H, ArH), 6.85 (d, J = 8.2 Hz, 1H, ArH), 4.07 (q, J = 7.0 Hz, 2H, OCH₂CH₃), 1.37 (t, J = 7.0 Hz, 3H, OCH₂CH₃), ¹³C NMR (125 MHz, DMSO-d₆) δ 169.2 (thiazole C2), 149.1 (Ar_{ipso}), 147.6 (thiazole C4), 142.9 (Ar_{ipso}), 139.3 (C=N), 133.1, 126.6, 126.2, 120.9 (Ar), 119.5 (CN), 116.2 (Ar), 111.1 (Ar_{ipso}), 109.9 (thiazole C5), 107.6 (Ar), 64.3 (CH₂), 15.2 (CH₃),

View Article Online RSC Advances

HRMS m/z 365.1063 $[M + H]^+$ calcd for $C_{19}H_{16}N_4O_2S$: 365.1072. Anal. for $3a' \cdot 1/5EtOH$, as isolated, calcd for $C_{19.4}H_{17.2}N_4O_{2.2}S$: C, 62.36; H, 4.64; N, 15.00. Found: C, 61.58; H, 4.23; N, 14.65%, corresponding to 99% purity. The residual solvent could be removed only under prolonged drying.

2.2.20 2-(2-(3,4-Dimethylbenzylidene)hydrazinyl)-4-(4-

cyanophenyl) thiazole (3t). Off-yellow solid (73% yield), mp 192-194 °C, R_f 0.46 (acetone/*n*-hexane, 1:3), λ_{max} 335 nm, IR (ATR) v_{max} 3294 (N−H), 3115, 2924 (C−H), 2227 (C≡N), 1604 (thiazole), 1575 (C=N), 1504, 1454, 1409, 1386 (C=C), 1051-709 (characteristic of thiazole) cm⁻¹, ¹H NMR (500 MHz, DMSO-d₆) δ 12.14 (s, 1H, NH), 8.03 (d, J = 8.4 Hz, 2H, ArH), 7.99 (s, 1H, HC=N), 7.86 (d, J = 8.4 Hz, 2H, ArH), 7.62 (s, 1H, thiazole-H), 7.42 (s, 1H, ArH), 7.38 (d, *J* = 7.7 Hz, 1H, ArH), 7.19 (d, *J* = 7.8 Hz, 1H, ArH), 2.26 (s, 3H, CH₃), 2.24 (s, 3H, CH₃), ¹³C NMR (125 MHz, DMSO d_6) δ 169.0 (thiazole C2), 149.3 (thiazole C4), 142.5, 139.3 (C= N), 138.4, 137.2, 133.2, 132.4, 130.4, 127.8, 126.6, 124.4 (Ar), 119.5 (CN), 110.0 (Ar_{ipso}), 107.9 (thiazole C5), 19.9 ($2 \times$ overlapping CH₃), HRMS m/z 333.1167 [M + H]⁺ calcd for C₁₉H₁₆N₄S: 333.1174. Anal. for 3t, as isolated, C19H16N4S: C, 68.65; H, 4.85; N, 16.85. Found: C, 68.33; H, 4.69; N, 16.52%, corresponding to >99% purity.

2.2.21 2-(2-(3,4-Dichlorobenzylidene)hydrazinyl)-4-(4-

cyanophenyl) thiazole (3u). Off-yellow solid (74% yield), mp 262–263 °C, $R_{\rm f}$ 0.48 (acetone/*n*-hexane, 1 : 3), $\lambda_{\rm max} = 343$ nm, IR (ATR) ν_{max} 3113 (N-H), 3100–2600 br (N-HBr salt and C-H overlapped), 2225 (C=N), 1629-1473 (thiazole), 1608 (C=N), 1556, 1373, 1271, 1222 (C=C), 1056-715 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 8.05–7.99 (m, 3H, ArH), 7.91 (d, J = 8.4 Hz, 2H, ArH), 7.86 (s, 1H, HC=N), 7.84 (s, 1H, ArH), 7.67-7.61 (m, 3H, overlapping thiazole-H and ArH), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.7 (thiazole C2), 149.3 (thiazole C4), 139.3 (HC=N), 135.6, 133.1, 132.8, 132.1, 132.1, 131.8, 131.5, 128.8, 126.6 (Ar), 119.4 (CN), 110.1 (Ar_{ipso}), 108.4 (thiazole C5), HRMS m/z 373.0161 $[M + H]^+$ calcd for $C_{17}H_{10}Cl_2N_4S$: 373.0081. Anal. analysis calcd (%) for $3u \cdot 1/2HBr$, as isolated, calcd for C17H10.5Br0.5Cl2N4S2: C, 49.35; H, 2.56; N, 13.54; found: C, 49.28; H, 2.30; N, 13.77%, corresponding to >99% purity for this salt.

2.2.22 2-(2-(2,4,6-Trimethylbenzylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3v). Beige solid (68% yield), mp 221– 223 °C, R_f 0.56 (acetone/*n*-hexane, 1:3), λ_{max} 340 nm, IR (ATR) ν_{max} 3298 (N–H), 2910 (C–H), 2218 (C=N), 1604 (thiazole), 1571 (C=N), 1479, 1411, 1382, 1332 (C=C), 1049–717 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 12.08 (s, 1H, NH), 8.41 (s, 1H, HC=N), 8.03 (d, J = 8.5 Hz, 2H, ArH), 7.86 (d, J= 8.5 Hz, 2H, ArH), 7.59 (s, 1H, thiazole-H), 6.92 (s, 2H, ArH), 2.42 (s, 6H, CH₃), 2.25 (s, 3H, CH₃), ¹³C NMR (100 MHz, DMSOd₆) δ 169.2 (thiazole C2), 149.4 (thiazole C4), 142.4, 139.3 (C= N), 138.2, 137.3, 133.1, 130.1, 128.2, 126.6 (Ar), 119.5 (CN), 110.0 (Ar_{ipso}), 107.7 (thiazole C5), 21.9 (CH₃), 21.2 (CH₃), HRMS m/z347.1324 [M + H]⁺ calcd for C₂₀H₁₈N₄S: 347.1330. Anal. for **3v**, as isolated, calcd for C₂₀H₁₈N₄S: C, 69.34; H, 5.24; N, 16.17. Found: C, 69.14; H, 5.11; N, 16.02%, corresponding to >99% purity.

2.2.23 2-(2-(2,4,6-Trifluorobenzylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3w). Yellow solid (72% yield), mp 270– 271 °C, $R_{\rm f}$ 0.43 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 331 nm, IR (ATR) $ν_{\rm max}$ 3273 (N–H), 3115 (C–H), 2216 (C≡N), 1606 (thiazole), 1573 (C=N), 1490, 1427, 1344, 1288 (C=C), 1035–738 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 12.40 (s, 1H, NH), 8.07 (s, 1H, HC=N), 8.03 (d, *J* = 8.5 Hz, 2H, ArH), 7.86 (d, *J* = 8.5 Hz, 2H, ArH), 7.65 (s, 1H, thiazole-H), 7.29 (app. t, *J* = 9.0 Hz, 2H, ArH), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.6 (thiazole C2), 149.4 (thiazole C4), 133.2, 131.2, 126.6 (Ar), 119.4 (CN), 110.1 (Ar_{ipso}), 108.6 (thiazole C5), 102.0 (Ar), not all signals could be observed due to *J*_{CF} couplings and low compound solubility, ¹⁹F NMR (375 MHz, DMSO-d₆) δ (ppm) –106.34 (app. d, *J* = 8.1 Hz, 1F), –109.73 (app. t, *J* = 8.1 Hz, 2F), HRMS *m*/z 359.0577 [M + H]⁺ calcd for C₁₇H₉F₃N₄S: 359.0578. Anal. for **3w**, as isolated, C₁₇H₉F₃N₄S: C, 56.98; H, 2.53; N, 15.64. Found: C, 56.88; H, 2.4; N, 15.42%, corresponding to >99% purity.

2.2.24 2-(2-(2,4,6-Trihydroxybenzylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3x). Brick red solid (74% yield), mp 264-265 °C, $R_{\rm f}$: 0.24 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 343 nm, IR (ATR) $\nu_{\rm max}$ 3113 (N-H) overlapped by br 3600–2600 (O-H, N-HBr and C-H), 2223 (C=N), 1604 (thiazole), 1473 (C=N), 1346, 1255 (C=C), 1147 (C-O), 1047 (characteristic of thiazole) cm^{-1} , ¹H NMR (400 MHz, DMSO-d₆) δ 10.42 (s, 1H, OH), 8.49 (s, 1H, HC= N), 8.02 (d, J = 8.5 Hz, 2H, ArH), 7.86 (d, J = 8.5 Hz, 2H, ArH), 7.59 (s, 1H, thiazole-H), 5.89 (s, 2H, ArH), ¹³C NMR (100 MHz, DMSO-d₆) δ 167.8 (thiazole C2), 161.6 (Ar_{ipso}), 159.3 (Ar_{ipso}), 149.4 (thiazole C4), 143.2, 139.0 (C=N), 133.2, 126.7 (Ar), 119.4 (CN), 110.2 (Ar_{ipso}), 106.9 (thiazole C5), 99.5 (Ar), 94.9 (Ar), HRMS m/z 353.0700 [M + H]⁺ calcd for C₁₇H₁₂N₄O₃S. Anal. for **30** · 1/2EtOH · 1/5HBr, as isolated, C₁₈H₁₅ ₂Br₀ ₂N₄O₃ ₅S: C, 55.21; H, 3.91; N, 14.31. Found: C, 55.47; H, 3.48; N, 14.04%, corresponding to >99% purity for this composition. The ethanol was removed on prolonged drying, but not the HBr.

2.2.25 2-(2-(3,4,5-Trimethoxybenzylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3y). Orange solid (77% yield), mp 197-199 °C, R_f 0.50 (acetone/*n*-hexane, 1:3), λ_{max} 347 nm, IR (ATR) ν_{max} 3500–3000 br (N–H and N–HBr), 2940 (C–H), 2227 (C \equiv N), 1600 (thiazole), 1565 (C=N), 1500, 1445, 1348, 1273 (C=C), 1137 (C-O stretching), 1020-700 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 8.04 (s, 1H, HC=N), 8.01 (d, J = 8.5 Hz, 2H, ArH), 7.86 (d, J = 8.5 Hz, 2H, ArH), 7.64 (s, 1H, thiazole-H), 6.98 (s, 2H, ArH), 3.83 (s, 6H, OCH₃), 3.70 (s, 3H, OCH₃), ¹³C NMR (100 MHz, DMSO-d₆) δ 169.0 (thiazole C2), 153.7 (Ar_{ipso}), 149.2 (thiazole C4), 146.4, 142.1 (Ar_{ipso}), 139.2 (C=N), 133.2, 132.9, 130.3, 128.8, 126.6 (Ar), 119.5 (CN), 110.0 (Ar_{ipso}), 108.0 (thiazole C5), 104.0 (Ar), 60.6 (CH_3) , 56.4 (CH_3) , 56.3 (CH_3) , HRMS m/z 395.1177 $[M + H]^+$ calcd for C₂₀H₁₈N₄O₃S: 395.1178. Anal. for 3y · 1/5HBr, as isolated, calcd for C₂₀H_{18.2}Br_{0.2}N₄O₃S: C, 58.50; H, 4.47; N, 13.64. Found: C, 59.19; H, 4.16; N, 13.16%, corresponding to 99% purity.

2.2.26 2-(2-(2,4,5-Trimethoxybenzylidene)hydrazinyl)-4-(4cyanophenyl) thiazole (3z). Dark grey solid (78% yield), mp 213– 214 °C, R_f 0.49 (acetone/*n*-hexane, 1 : 3), λ_{max} 353 nm, IR (ATR) ν_{max} 3109 (N–H), 2935 (C–H) overlapped by (N–HBr), 2223 (C=N), 1604 (thiazole), 1571 (C=N), 1478, 1359, 1278, 1205 (C=C), 1134 (C–O), 1024–738 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, CDCl₃) δ 8.28 (s, 1H, HC=N), 7.90 (d, J = 8.5 Hz, 2H, ArH), 7.70 (d, J = 8.5 Hz, 2H, ArH), 7.40 (s, 1H, thiazole-H), 6.98 (s, 1H, ArH), 6.48 (s, 1H, ArH), 3.96 (s, 3H, OCH₃), 3.93 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃); ¹³C NMR (100 MHz, CDCl₃) δ 168.9 (thiazole C2), 153.8 (Ar_{ipso}), 152.7 (Ar_{ipso}), 145.1 (Ar_{ipso}), 143.7 (thiazole C4), 142.4, 135.7 (C=N), 132.8, 126.3 (Ar), 118.6 (CN), 113.0, 112.0 (Ar), 108.2 (Ar_{ipso}), 105.3 (thiazole C5), 96.5 (Ar), 56.4 (CH₃), 56.3 (CH₃), 56.1 (CH₃), HRMS *m*/*z* 395.1171 [M + H]⁺ calcd for C₂₀H₁₈N₄O₃S: 395.1178 Anal. calcd (%) for **3z**·1/5HBr, as isolated, C₂₀H_{18.2}Br_{0.2}N₄O₃S: C, 58.50; H, 4.47; N, 13.64. Found: C, 58.55; H, 4.29; N, 13.48%, corresponding to >99% purity for this salt.

2.2.27 2-(2-((Pentafluorophenyl)methylene)hydrazinyl)-4-(4-cyanophenyl) thiazole (3a'). Yellow solid (67% yield), mp 279-280 °C, $R_{\rm f}$ 0.40 (acetone/*n*-hexane, 1:3), $\lambda_{\rm max}$ 335 nm, IR (ATR) v_{max} 3315 (N-H), 3130 (C-H), 2216 (C≡N), 1571 (C=N), 1517, 1489, 1409, 1361 (C=C), 1056-705 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆) δ 12.66 (s, 1H, NH), 8.05 (d, J = 8.4 Hz, 2H, ArH), 8.03 (s, 1H, HC=N), 7.88 (d, J = 8.4 Hz, 2H, ArH), 7.71 (s, 1H, thiazole-H); ¹³C NMR (100 MHz, DMSO-d₆) δ 142.1, 137.8 (C=N), 133.2, 129.4, 126.6 (Ar), 119.4 (CN), 110.2 (Ar_{ipso}), not all signals could be observed due to multiple J_{CF} couplings and low compound solubility, ¹⁹F NMR (375 MHz, DMSO-d₆) δ -143.17 (app. dd, 2F, J = 22.6, 7.3 Hz), -154.78 (app. t, 1F, J = 22.6 Hz), -162.85 (app. td, 2F, J = 22.6, 7.3 Hz), HRMS m/z 395.0383 $[M + H]^+$ calcd for $C_{17}H_7F_5N_4S$: 395.0390. Anal. for 3a', as isolated, calcd for $C_{17}H_7F_5N_4S$: C, 51.78; H, 1.79; N, 14.21. Found: C, 51.66; H, 1.74; N, 13.92, corresponding to >99 purity.

2.2.28 2-(2-((3-Bromothiophen-2-yl)methylene)hydrazinyl)-4-(4-cyanophenyl) thiazole (3b'). Beige solid (73% yield), mp 223-225 °C, Rf 0.45 (acetone/n-hexane, 1:3), λ_{max} 350 nm, IR (ATR) *v*_{max} 3174 (N−H), 3099 (C−H), 2227 (C≡N), 1608-1411 (thiazole), 1573 (C=N), 1489, 1446, 1350, 1271 (C=C), 1053-700 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO d_6) δ 12.39 (s, 1H, NH), 8.22 (s, 1H, HC=N), 8.03 (d, J = 8.5 Hz, 2H, Ar-H), 7.86 (d, J = 8.5 Hz, 2H, Ar-H), 7.70 (d, J = 5.4 Hz, 1H, thiophene-H), 7.65 (s, 1H, thiazole-H), 7.17 (d, I = 5.4 Hz, 1H, thiophene-H), ¹³C NMR (100 MHz, DMSO-d₆) δ 168.3 (thiazole C2), 149.3 (thiazole C4), 139.1 (HC=N), 135.4, 134.1, 133.2 (Ar), 131.2 (thiophene C2), 129.2 (thiophene C5), 126.6 (thiophene C4), 119.4 (CN), 112.1 (Ar_{ipso}), 110.1 (thiophene C3), 108.4 (thiazole C5), HRMS m/z 388.9527, $[M + H]^+$ calcd for $C_{15}H_9BrN_4S_2$ 388.9530. Anal. for $3b' \cdot 1/6EtOH$, as isolated, calcd for C₁₅H_{10.33}BrN₄O_{0.67}S₂: C, 44.90; H, 2.60; N, 13.96. Found: C, 44.93; H, 2.35; N, 13.52%, corresponding to >99% purity for this solvate. The residual solvent was easily removed under drying.

2.2.29 2-(2-((4-Bromothiophen-2-yl)methylene)hydrazinyl)-4-(4-cyanophenyl) thiazole (3c'). Yellow solid (75% yield), mp 240–242 °C, R_f 0.48 (acetone/*n*-hexane, 1:3), λ_{max} 348 nm, IR (ATR) ν_{max} 3307 (N–H), 3107 (C–H), 2218 (C=N), 1604 (thiazole), 1571 (C=N), 1517, 1483, 1406, 1348 (C=C), 1053–698 (characteristic of thiazole) cm⁻¹, ¹H NMR (500 MHz, DMSO-d₆) δ 12.36 (s, 1H, NH), 8.19 (s, 1H, thiophene-H), 8.03 (d, J = 8.5 Hz, 2H, ArH), 7.87 (d, J = 8.5 Hz, 2H, ArH), 7.69 (s, 1H, thiophene-H), 7.65 (s, 1H, thiazole-H), 7.42 (s, 1H, HC=N), ¹³C NMR (125 MHz, DMSO-d₆) δ 168.4 (thiazole C2), 149.4 (thiazole C4), 141.0 (thiophene C2), 139.1 (C=N), 135.9, 133.2 (Ar), 131.2 (thiophene C3), 126.6 (thiophene C5), 125.4 (Ar), 119.4 (CN), 110.1 (Ar_{ipso}), 109.7 (thiophene_{ipso}), 108.4 (thiazole C5), HRMS *m*/z 388.953 $[M + H]^+$ calcd for $C_{15}H_9BrN_4S_2$: 388.9530. Anal. for 3c', as isolated, $C_{15}H_9BrN_4S_2$: C, 46.28; H, 2.33; N, 14.39. Found: C, 46.16; H, 2.22; N, 14.13, corresponding to >99% purity.

2.2.30 2-(2-((4,5-Dimethylthiazol-2-yl) methylene) hydrazinyl)-4-(4-cyanophenyl) thiazole (3d'). Turmeric yellow solid (69% yield), mp 262-263 °C, Rf 0.37 (acetone/n-hexane, 1: 3), λ_{max} 367 nm, IR (ATR) ν_{max} 3174 (N-H), 3070, 2920 (C-H), 2223 (C=N), 1606-1433 (thiazole), 1577 (C=N), 1471, 1346, 1278, 1251 (C=C), 1055-738 (characteristic of thiazole) cm⁻¹, ¹H NMR (400 MHz, DMSO-d₆): δ 12.50 (s, 1H, NH), 8.08 (s, 1H, HC=N), 8.01 (d, I = 8.4 Hz, 2H, ArH), 7.85 (d, I = 8.4 Hz, 2H, ArH), 7.64 (s, 1H, thiazole-H), 2.35 (s, 3H, CH₃), 2.25 (s, 3H, CH₃), ¹³C NMR (100 MHz, DMSO-d₆) δ 149.7 (thiazole C4), 136.8 (HC=N), 133.2, 130.0, 128.3, 126.6 (Ar), 119.4 (CN), 108.7 (thiazole C5), 14.9 (thiazole, C4-CH₃), 11.7 (thiazole, C5-CH₃), not all signals could be observed due to low compound solubility, HRMS m/z 340.0684 $[M + H]^+$ calcd for $C_{16}H_{13}N_5S_2$: 340.0690. Anal. $3d' \cdot 1/6EtOH$, as isolated, calcd for C_{16,33}H₁₄N₅O_{0,17}S₂: C, 56.52; H, 4.07; N, 20.18. Found: C, 56.17; H, 3.71; N, 20.18%, corresponding to >99% purity for this solvate. The residual solvent could be removed only under prolonged drying.

2.3. Biological methods

2.3.1 Cell culture. The carcinoma cell lines used in anticancer biological experiments were from the American Type Tissue Cell Culture Collection (ATCC), cultivated in nutritional medium (RPMI 1640) supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) glutamine. Cell lines were passaged twice weekly and cultured at 37 °C in a 5% CO2 maintained incubator to maintain logarithmic growth. To decrease genotypic/ phenotypic drift, \leq 30 passaged cells used in the experiments. All compounds were dried prior to biological screening. Milligram quantities of cisplatin and compounds 3a-d' were weighed using an ultra-micro balance (accurate to ± 0.02 mg). Fresh stock solutions (10 mM) of trialled compounds and cisplatin controls were prepared in DMSO for each experiment, and all experiments were performed in triplicate. Colon cancer cell line (HCT-116), breast cancer cell line (MCF-7) and noncarcinogenic MRC-5 fibroblasts were used in the investigation.

2.3.2 MTT cell viability assay. MTT assays were used to evaluate the cell viability of HCT-116, MRC-5, and MCF7 cells, as described by Mosmann in 1983.26 In 96 well plates cells were seeded (180 µL per well). To allow exponential growth, cells were seeded at 3×10^3 cells per well and incubated for 24 h at 37 °C/ 5% CO₂ prior to test agent introduction. From the stock solution, serial dilutions were made in nutrient medium to achieve final concentrations of 0.05 µM, 0.1 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 20 µM, and 50 µM, respectively. The T0 plate was read at the time of test agent addition, and the other plates after 72 h exposure to test agents. All plates were incubated for another 2.5 h following addition of 50 μ L MTT solution (5 mg mL⁻¹ PBS). The supernatant was removed from each well, and 150 μ L DMSO was added. Depending on the number of viable cells, a colour change of varying intensity (purple colour) was detected. At a wavelength of 550 nm, absorbance was measured with a 2104 EnVision® multilabel plate reader. GI_{50} values (concentration required to achieve 50% growth inhibition) were calculated by interpolation, using standard procedures as detailed previously.⁶

2.3.3 Cell counts. While MTT assay is commonly used to assess cell viability and proliferation there are several drawbacks to this approach, such as false positive results caused by chemicals that may reduce the MTT (irrespective of any cellular process). Therefore a cell count test was used to confirm our MTT results. Cells were harvested and counted in the same way as for the MTT experiment, seeded at a density of 2×10^4 in 6-well plates. After being treated with test compounds at concentrations of 5 and 10 μ M, the cells were grown for 72 h. A haemocytometer was used to count the cells.

2.3.4 Clonogenic assay. Clonogenic assays were carried out by seeding 400 cells per well in 6-well plates with 2 mL medium and allowing them to attach for 24 h. A haemocytometer was used to count the cells. Cells were treated with 3 at 5 and 10 μ M concentrations, as guided by the initial MTT studies. The medium alone was used as a control. After 24 h of compound exposure, the medium was aspirated and washed with 1 mL of cold PBS. Fresh medium (2 mL) was added, and the cells were incubated at 37 °C. Daily inspection was conducted until colonies of \geq 50 cells established in the control wells. Colonies were washed in PBS before being fixed in 100 percent methanol (0.5 mL) for 15 minutes. Finally, 0.7 mL of 0.05 percent methylene blue was used for staining (water : methanol 1 : 1). The number of cell colonies were counted.

2.3.5 Cell cycle assay. Cell cycle analyses were performed by the method reported by Nicoletti.27 In a 10 cm Petri dishes cells were seeded with 10 mL medium, density of 7×10^5 (control, 24 h) and 4×10^5 (48 and 72 h) cells per dish. After 24 h incubation at 37 °C cells were treated with desired concentrations of the synthesized compounds (5 and 10 µM). The medium and flocculent cells were transferred to a 15 mL Falcon tube after treatment period. The harvesting of cells was achieved by adding 0.5 mL of 1× trypsin EDTA solution. After cells had detached, they were added to the falcon tube and content were centrifuged at 1200 rpm for 5 min at 4 °C in a Beckman Coulter Allegro 33. Supernatant was removed and pellet was broken down ensuing 1 mL PBS addition and the tubes were vortexed and centrifuged twice and the cells were suspended in 0.7 mL cold hypotonic fluorochrome solution. In a labelled (FACS) fluorescence activated cell sorter tube cells were transferred and stored overnight at 4 °C in dark. To attain single cell suspensions the cells were vortexed. A total of 10 000 events were recorded for each sample which were counted using a FC500 Beckman Coulter flow cytometer and the results were analysed by using WEASEL.6

2.3.6 Caspase-3/7 **activity assay.** Caspase-3/7 activity was determined by Apo-ONE® homogeneous caspase-3/7 assay (Promega).⁶ In 96 well opaque white cell culture plates, 3×10^3 per well cells were seeded and incubated at 37 °C for 24 h followed by addition of compounds **3b**' and **3f** (*i.e.* 5 and 10 μ M for 72 h exposure). Apo-ONE® caspase-3/7 reagent was added to each well, gently mixed at 300–500 rpm for 30 seconds followed by incubation for 30 min at room temperature. The EnVision

multilabel plate reader (PerkinElmer) was used to measure the well fluorescence at wavelengths between 499 nm and 521 nm.

2.3.7 Western blot assay. Western blotting was carried out using method reported.²⁸ Suitable 10 cm² dishes cells were seeded at a density of $1-2 \times 10^6$ per dish and allowed to attach for 24 h prior to exposure to 5 μ M and 10 μ test compounds. Cell lysates were prepared after the desired treatment period, protein concentrations were determined using the Bradford assay.²⁹ SDS PAGE was used to separate the proteins (50 μ g each sample) which were then transferred to a nitrocellulose membrane. Primary antibodies to PARP-1, and GAPDH were from Promega UK. Immunoblotting was used to detect the proteins, as previously described.³⁰ ImageJ software was used for densitometric analyses.

3. Results and discussion

3.1. Synthesis of 4-substituted 2-hydrazinylthiazole species(3)

A library of 30 compounds was prepared using α -bromo-4cyanoacetophenone (2, $R^1 = 4$ -C₆H₄CN in all cases) from a range of readily available thiosemicarbazones (1a–d').^{17–25} Reflux of the reaction components in ethanol for 3–3.5 h afforded modest to good yields of 3a–d' (Table 1) all of which could be isolated by simple filtration of directly precipitated products.

Across the library of 30 thiazoles (3a-d') the average purity was 98% with a standard deviation of 2%, based on elemental analysis data. Combustion analyses also revealed that traces of water/EtOH or low levels of product protonation by the HBr reaction by-products that fully accounted for the minor impurities. The HBr/H2O impurities can be seen by IR (where they cause a shallow broad ν OH feature to develop 3600–2500 cm⁻¹ due to extensive hydrogen bonding) but are best detected particularly by CHN combustion analysis. They are not easily quantified by NMR. All compounds 3 were of the desired formulation, except for 3u, where the hemi-HBr salt was the major product on the basis of combustion analysis. The latter compound was not further purified due to its low biological activity in preliminary studies (GI_{50} value 12.8 \pm 0.7 μM and $27.2\pm0.5~\mu\text{M}$ against MCF-7 and HCT-116 carcinoma cell lines, see later). It proved challenging to obtain accurate CHN combustion data on fluorine-containing compounds 3r, 3t and 3w, and this may reflect their resistance to combustion. The data presented represents the lower limit on their purity, which is still >95%. Issues associated with attaining high accuracy CHN analyses of F-containing organic compounds are well known.31 All compounds were extensively dried before use in biological assay.

Multinuclear NMR studies are also in line with isolated 3 analogues having purities of 95-98+% and confirm that proposed connectivity has been isolated. The observation of appropriate HRMS $[M + H]^+$ also support the isolation of the desired targets. In all cases the presence of an azomethine linkage is confirmed by a ¹³C NMR signal in the range of 138.5-147.7 ppm. The presence of the hydrazone is evidenced by the presence of characteristic amine (3348–3174 cm⁻¹) and imine

		$H_2N \qquad NH \qquad R^3$	+ Br 2	EtOH reflu: (3 to 3.4	$\frac{1}{x}$		2
(3)	R^2	R ³	Yield (%)	(3)	R ²	R ³	Yield (%)
a	н	F	69	р	Н	Br.	70
b	Н	F	79	q	Н	F ₃ C	78
с	Me	Br	70	r	Н	O2N Br	71
d	Н	l L	67	s	н	HO	76
e	Ме	F	70	t	н		73
f	Н	OH 	73	u	н	CI	74
g	н	CI	78	v	н		68
h	Н	H Br	70	w	н	F	72
i	Н		75	x	н	но-С-С-С-	74
j	н	OMe 	72	у	н	MeO MeO MeO	77
k	н	MeO-	65	z	н	MeO MeO	78
1	н	MeO	71	a′	н	F F F F F	67
m	Н	F ₃ C-CF ₃	66	b′	н	Br S	73
n	Н	CI CI	68	c′	н	Br	75
0	Н	MeO 	75	ď	н	N S	69

 Table 1
 4-Cyanophenyl-2-hydrazinylthiazole species (3) prepared in this study

 $(1629-1408 \text{ cm}^{-1})$ stretches in the solid state IR spectra. In the latter case the band is sometimes overlapped by thiazole skeletal vibrations. ¹³C NMR spectroscopy is diagnostic of the substitution pattern in the thiazole: C2 appears in the range 167.8-170.6 ppm, C4 at 149.3-155.2 ppm while C5 appears at 105.3-109.9 ppm. Although well suited to aqueous biological studies at millimolar and lower concentrations, compounds 3 are poorly soluble in many organic solvents. Fully assigned ¹³C NMR spectra could be attained in most cases, but those 3 containing extensively fluorine-coupled carbons proved problematic, even for long spectral accumulation times. The ¹H NMR spectra of 3a-d' are unremarkable, but indicate the presence of the connectivity proposed in Table 1. By performing our analyses in DMSO-d₆ we could slow NH exchange allowing this to also be observed at *ca.* 12.5 ppm. The studies proved that compounds with similar core exist in trans form,^{32,33} hence synthesized compounds should also exist in trans configuration.

3.2. Biological evaluation

3.2.1 MTT assayed anti-cancer activity. The growth inhibitory potential of 3a-d' against the HCT-116 and MCF-7 cancer cell lines was determined by MTT assays. Potential growth inhibitory selectivity for carcinoma cell lines over normal cells was also probed using MRC-5 fibroblasts. Results of MTT assays were corroborated by cell count assays. Further, clonogenic assays were performed to determine cancer cell survival and retention of proliferative capacity after a brief challenge with test agent. The effects of the agents 3 on cell cycle perturbation and interrogation of apoptotic cell death were examined by flow cytometry, caspase activation and western blot assays. Growth inhibitory potential of 3a-d' was compared with cisplatin as a positive control (Table 2). Using standard MTT methods,⁶ GI₅₀ values (the concentration of test agent that inhibits cell growth by 50%) were calculated. The selectivity of compounds 3 towards cancer cell lines was determined by comparing their activity against normal human lung fibroblast (MRC-5) cells. Consequently, selectivity indices (SIs) were calculated for both cisplatin and the tested compounds 3.

3.2.2 Effect of substituent R³ on the anti-cancer activity of 3 (SAR). Pleasingly from the array of compounds prepared, the majority of compounds were highly active in both cancer cell lines tested (Table 1 and Fig. 2). In fact, the majority of compound series 3 analogues are more active than the cisplatin positive control as cisplatin GI_{50} values of 7.5 \pm 0.7 and 9.8 \pm 0.2 µM against MCF-7 and HCT-116 cells respectively were recorded. The GI₅₀ value of 9.7 µM against MRC-5 fibroblasts demonstrates the limited therapeutic window of cisplatin; cisplatin exhibited poor SIs of 0.9 and 1.3 for HCT-116 and MCF-7 respectively. The results (Table 2) indicated that only two compounds (3w and 3o) have appreciably greater activity against the MRC-5 cell line when compared with MCF-7 and HCT-116. Most other compounds are more selective towards carcinoma cell lines (3i is marginal). Compound 3f substituted with 2-hydroxy-3-methyl functionality was the most potent dual growth inhibitor from the library with $ext{GI}_{50}$ values of 1.0 \pm 0.1

	GI ₅₀ values	(M) mean \pm	SD	Selectivity indices (SI)										
	MCF-7	HCT-116	MRC-5	MCF-7	HCT-116	MW	$c \log P^c$	LE (MCF-7)	LE (HCT-116)	tPSA ^d	Nrot ^d	HBA^d	HBD^d	
			Ν	1ono substitute (3) o,m,p R ³	ed ج	F b	−ξ− c	→ to the second	F					
a b c d e	3.4 ± 1.0 36.6 ± 1.4 8.1 ± 0.6 2.3 ± 0.2 28.5 ± 0.8	$\begin{array}{c} 3.1 \pm 1.5 \\ 2.2 \pm 0.5 \\ 6.9 \pm 0.4 \\ 11.3 \pm 0.7 \\ 6.9 \pm 0.2 \end{array}$	$\begin{array}{c} 16.6 \pm 0.1 \\ 16.8 \pm 0.5 \\ 17.0 \pm 0.5 \\ 34.9 \pm 0.3 \\ 44.7 \pm 0.2 \end{array}$	4.9 0.5 2.1 15.2 1.6	5.4 7.6 2.5 3.1 6.5	322.4 322.4 397.3 430.3 336.4	3.83 3.85 4.72 4.77 4.1	0.33 0.26 0.29 0.33 0.26	0.33 0.34 0.29 0.29 0.29	89 89 89 89 89	4 4 4 4 4	4 4 4 4 4	1 1 1 1 1	
	GI ₅₀ values	(M) mean \pm	Selectivity indices (SI)											
	MCF-7	HCT-116	MRC-5	MCF-7	HCT-116	MW	$c \log P^c$	LE (MCF-7)	LE (HCT-116)	tPSA ^d	Nrot ^d	HBA^d	HBD^d	
			C	i substituted (3) (o,m) R ³	− − F		Br h		- Δ MeO j					
f g h i j k	$\begin{array}{c} 1.0 \pm 0.4 \\ 4.1 \pm 0.4 \\ 7.0 \pm 0.3 \\ 7.1 \pm 0.3 \\ 3.7 \pm 0.4 \\ 36.8 \pm 2.7 \end{array}$	$\begin{array}{c} 1.6 \pm 0.1 \\ 9.7 \pm 0.4 \\ 4.4 \pm 0.3 \\ 8.0 \pm 0.3 \\ 6.9 \pm 2.5 \\ 37.0 \pm 0.9 \end{array}$	$\begin{array}{c} 17.3 \pm 0.7 \\ 16.8 \pm 0.7 \\ 15.8 \pm 0.2 \\ 6.2 \pm 0.4 \\ 22.5 \pm 0.1 \\ 16.1 \pm 0.2 \end{array}$	17.3 4.1 2.3 0.9 6.1 0.4	10.8 1.7 3.6 0.8 3.3 0.4	334.4 354.8 399.3 332.4 364.4 348.4	3.85 4.31 4.54 4.54 3.75 4.14	0.34 0.31 0.29 0.29 0.28 0.24	0.33 0.28 0.31 0.29 0.27 0.24	110 110 110 89 108 99	4 4 4 6 5	5 5 4 6 5	2 2 1 1 1	
	GI ₅₀ values	s (M) mean \pm	SD	Selectivity indices (SI)										
	MCF-7	HCT-116	MRC-5	MCF-7	HCT-116	MW	$c \log P^c$	LE (MCF-7)	LE (HCT-116)	tPSA ^d	Nrot ^d	HBA^d	HBD^d	
	Di substituted (3) (o,p) and (o,o) \mathbb{R}^3 MeO k I m n Cl													
l m n	$9.2 \pm 0.4 \ 2.0 \pm 0.8 \ 25.4 \pm 1.6$	$\begin{array}{c} 8.4 \pm 0.9 \\ 4.7 \pm 1.3 \\ 1.1 \pm 0.5 \end{array}$	30.1 ± 0.6 16.5 ± 0.6 12.1 ± 0.4	3.3 8.3 0.5	3.6 3.5 11	364.4 440.4 373.3	3.75 5.43 4.97	0.26 0.26 0.26	0.27 0.24 0.34	108 89 89	6 6 4	6 4 4	1 1 1	
	GI ₅₀ values	(M) mean \pm	SD	Selectivity indices (SI)										
	MCF-7	HCT-116	MRC-5	MCF-7	HCT-116	MW	$c \log P^c$	LE (MCF-7)	LE (HCT-116)	tPSA ^d	Nrot ^d	HBA^d	HBD^d	
				Di substitu (3) (<i>m,m</i>) I	MeO R ³ MeO o		F Br p	F ₃ C q Ι	sN βr r					
o p q r	47.8 ± 1.1 7.3 ± 0.2 2.6 ± 0.1 4.1 ± 0.4	35.6 ± 1.1 8.1 ± 0.2 2.2 ± 0.1 3.0 ± 1.0	16.5 ± 0.5 17.7 ± 0.7 9.0 ± 0.1 12.2 ± 0.6	0.4 2.4 3.5 3	0.5 2.2 4.1 4.1	364.4 401.3 390.4 428.3	3.75 4.61 4.7 4.41	0.22 0.29 0.28 0.28	0.23 0.29 0.29 0.29	108 89 89 135	6 4 5 5	6 4 4 7	1 1 1 1	

Table 2Activity of 2-(2-benzylidenehydrazinyl)-4-(4-cyanophenyl) thiazole (3a-d') against MCF-7 and HCT-116 cancer cell lines and normalMRC-5 fibroblasts, as determined by MTT in vitro studies^{a,b} and SAR analysis^{c,d}

	GI ₅₀ values	s (M) mean \pm	SD	Selectivity indices (SI)									
	MCF-7	HCT-116	MRC-5	MCF-7	HCT-116	MW	$c \log P^c$	LE (MCF-7)	LE (HCT-116)	tPSA ^d	Nrot ^d	HBA^d	HBD^d
				Di	substituted (3) HO· (<i>m</i> , <i>p</i>) R ³	EtO s	ş		ξ- μ				
s t u	$7.3 \pm 0.8 \ 4.5 \pm 1.4 \ 12.8 \pm 0.7$	$8.4 \pm 0.6 \ 6.5 \pm 2.6 \ 27.2 \pm 0.5$	$\begin{array}{c} 18.1 \pm 0.4 \\ 13.2 \pm 0.3 \\ 30.4 \pm 0.2 \end{array}$	2.5 2.9 2.4	2.2 2 1.1	364.4 332.4 373.3	3.43 4.54 5	0.27 0.30 0.28	0.27 0.29 0.26	119 89 89	6 4 4	6 4 4	2 1 1
	GI ₅₀ value	es (M) mean ±	= SD	Selectivity indices (SI)									
	MCF-7	HCT-116	MRC-5	MCF-7	HCT-116	MW	$c \log P^c$	LE (MCF-7)	LE (HCT-116)	tPSA ^d	Nrot ^d	HBA ^d	HBD^d
			Tri substituted (3) (<i>o</i> , <i>o</i> , <i>p</i>) and (<i>mixed</i>) R ³		γ →ξ·F-√ ` w			ОН МеО 	y MeO	OMe			
v w x y z	$egin{array}{llllllllllllllllllllllllllllllllllll$	4.0 ± 1.0 1.5 ± 0.8 4.7 ± 0.3 1.6 ± 0.4 1.9 ± 0.5	$\begin{array}{c} 11.2 \pm 0.3 \\ 1.1 \pm 0.5 \\ 15.8 \pm 0.5 \\ 23.4 \pm 0.3 \\ 21.8 \pm 0.2 \end{array}$	2.7 0.2 6.9 8.7 8.7	2.8 0.7 3.4 14.6 11.5	346.5 358.3 352.4 394.5 394.5	4.91 4.06 3.07 3.34 3.34	0.29 0.28 0.30 0.27 0.27	0.29 0.32 0.29 0.28 0.28	89 89 150 117 117	4 4 7 7	4 4 7 7 7	1 1 4 1 1
	GI	50 values (M)	mean \pm SD	Selectivity indices (SI)									
	M	CF-7 HCT	<u>116</u> MRC-5	5 <u>M</u> C	$\frac{\text{CF-7}}{(3)} \xrightarrow{\text{HCT-1}}_{F}$	III6 MV	$\frac{c \log}{Br}$	$\frac{P^{c}}{Br} = \frac{\text{LE (MCF-T)}}{s}$	$\frac{1}{\frac{1}{1}} \frac{1}{\frac{1}{1}} \frac{1}{\frac{1}{1}} \frac{1}{\frac{1}{$) tPSA ^d	Nrot ^d	HBA ^d	HBD ^d
a' b' c' d' cist	1.7 3.9 4.3 9.0 platin ^b 7.5	$7 \pm 0.3 4.2 = 0 \pm 0.5 1.6 = 0 \pm 0.3 6.2 = 0 \pm 1.2 4.4 = 0 \pm 1.2 4.4 = 0 \pm 0.7 9.8 $	$\begin{array}{c} \pm 1.0 & 11.6 \pm \\ \pm 0.2 & 19.5 \pm \\ \pm 0.5 & 7.6 \pm \\ \pm 0.2 & 22.5 \pm \\ \pm 0.2 & 9.7 \pm \end{array}$	0.6 6.8 0.3 5 0.1 1.8 02 2.5 0.4 1.3	2.8 12.2 1.2 5.1 6 0.9	394 389 389 339	1.3 4.24 0.3 4.35 0.3 4.35 0.4 4.35	0.29 0.33 0.33 0.30	0.27 0.36 0.32 0.32	89 118 118 130	4 4 4 4	4 4 4 5	1 1 1 1

^{*a*} Data obtained from three independent trials; n = 3 per experimental condition per trial. ^{*b*} Used as positive control. ^{*c*} $c \log P$ calculated using Molinspiration.^{38 d} Data calculated using DataWarrior.³⁹

 μ M and 1.6 \pm 0.1 μ M against MCF-7 and HCT-116 cells respectively, and due to its low molecular weight led to satisfactory ligand efficiency values for both cell lines. Compound **3f** also demonstrated good selectivity with SI > 10 over MRC-5 fibroblasts. The $c \log P$ for this compound was calculated as 3.85, indicating the potential for good oral bioavailability.^{34,35} Pentafluorosubstituted compound **3a**' shows comparable potency to **3f** against MCF-7 cells but with increased lipophilicity and maintaining a MRC-5 SI of 6.8. Compound **3m** bearing two trifluoromethyl groups at positions 2 and 4 is also a potent growth inhibitor with GI₅₀ 2.0 \pm 0.8 μ M but with unfavourable lipophilicity. Compound **3n** (R³ = 2,6-Cl₂C₆H₃) was most active against HCT-116 showing a GI₅₀ value 1.1 \pm 0.5 μ M but with a calculated lipophilicity value of 4.97, compound **3n** presents a less favourable lead than **3f** against HTC-116 cells with a comparable MRC-5 SI. An interesting trend can be observed in the 3-halogen substituted compounds **3b–d**. An inverse relationship to size can be seen for potency against MCF-7 and HCT-116 cells. 3-Fluorosubstituted compound **3b** shows poor activity against MCF-7 cells (36.6 μ M) but highly potent against HCT-116 cells at 2.2 μ M. Inversely, 3-iodosubstituted compound **3d** shows good potency against MCF-7 cells (GI₅₀ 2.3 μ M); but a 5-fold reduction in potency against HCT-116 cells, indicating that the size of the substituent in the *meta*-position has an influence on activity and that smaller substituents in this position may negatively impact MCF-7 potency.



Fig. 2 Correlation plot between MCF-7 and HCT-116 GIC_{50} values. Cisplatin control shown in orange.

Fluorine substitution in the para-position was equally poorly active against MCF-7 cells with a 3-fold decrease in activity against HCT-116 cells. Compounds 3b'-d' replace the aryl ring with heterocyclic isosteres. Compound 3b' demonstrates good anti-cancer potency against both cancer cell lines with SI values of 5.0 and 12.2 respectively. 2-Bromothiophene compound 3c' shows comparable potency to 3b' against MCF-7 cells but shows comparable cytotoxicity resulting in a poor selective index. The 3-bromothiophene containing compound 3d' displays modest growth inhibition against HCT-116 cells, with an improved SI of 5.1. Considering the methoxy substituted compounds 3j, 3l, 3o, 3y and 3z respectively it can be seen that the substitution pattern of the aromatic ring has a significant effect on the potency of the compound. For example, the introduction of a 4position methoxy group to compound 30 to yield 3y increases the activity against MCF-7 and HCT-116 cells decreasing GI₅₀ values from 47.8 \pm 1.1 μM and 35.6 \pm 1.1 μM to 2.7 \pm 0.1 and 1.6 µM respectively. The same methoxy addition to compound 3j provides 3z which benefits from a 3.5-fold increase in activity against HCT-116 cells with no significant change in activity against fibroblasts, resulting in an improved SI from 3.3 to 11.5. Interestingly, 2,4-methoxy substituted compound 31 shows reduced potency against both cancer cell lines along with no significant activity against MRC-5. However, the need to add additional methoxy groups to improve the selectivity results in decreased ligand efficiency for these compounds. The use of electron-donating methoxy groups reduces fibroblast toxicity compared to other electron donating groups. Compounds 3i and 3j have similar overall molar refractivity 102.8 cm³ mol⁻¹ and 105.5 $\text{cm}^3 \text{ mol}^{-1}$ respectively; with comparable anticancer activity - but significantly different activity toward MRC-5 cells. Substitution with additional methoxy groups results in decreased in lipophilicity in compounds 3y and 3z showing good drug-like properties commensurate with oral bioavailability in line with compliance to Lipinski and Veber guidelines with modest ligand efficiency improved lipophilic efficient than 3f.³⁵⁻³⁷ Clearly, substitution on the aromatic ring in the R^3 position can strongly influence the overall activity of these

compounds; however, a wider scope library would be needed to fully investigate the nuances of the structure-activity relationships. As the electronic effects of substituents are not correlated to electron withdrawing or donating substituents as can be seen with the comparable potencies of 3a' (pentafluoro) and 3y (3,4,5-methoxy) in both cell lines.

3.2.3 Cell count studies. To corroborate MTT studies, compounds with potent *in vitro* anticancer activity (**3f**, **3m**, **3n**, **3a**' and **3b**') were selected for cell count experiments (Fig. 3).

These investigations show compound **3n** ($\mathbb{R}^3 = 2,6$ -dichlorophenyl) inhibited HCT-116 growth significantly, (50–55% of the untreated control sample at 5 µM and 100% at 10 µM). Additionally, **3b**' ($\mathbb{R}^3 = 3$ -bromothiophene) exhibited 50–55% inhibition at 5 µM and 90–95% at 10 µM against HCT-116. Compound **3f** ($\mathbb{R}^3 = 2$ -hydroxy-3-methylphenyl) inhibited MCF-7 by 100% at 10 µM and 55–60% at 5 µM. At a concentration of 10 µM, compounds **3a**' ($\mathbb{R}^3 = 1,2,3,4,5$ -pentafluorophenyl) exhibited 90–95% growth inhibition and **3h** ($\mathbb{R}^3 =$ 2,4-bis(trifluoromethyl)phenyl) showed 65–70% inhibitory potential.

3.2.4 Clonogenic assays. The ability of single cells (HCT 116 and MCF-7) to survive brief challenge (24 h) by 3 and survive to produce progeny colonies was determined by clonogenic assay. Selected 3 analogues were interrogated at 5 and 10 μ M. Fig. 4 shows results of clonogenic assays. The number of colonies formed after brief exposure to test agents are represented as survival fractions (in % values) of control colony numbers. After 24 h treatment compounds 3 strongly suppressed cell colony formation at 5 and 10 μ M concentrations. Compounds 3a, 3b, 3f, 3n, 3v, 3w, 3z, 3a' and 3b' are presented in Fig. 3A, all



Fig. 3 Cell count assay for selected compounds against MCF-7 and HCT-116 cells. Cells were seeded at a density of 2×10^4 per well; counts were performed following 72 h exposure to test agent. Data represented as % control, mean \pm SD for 2 independent experiments performed in triplicate. Significance is reported as *p < 0.01, **p < 0.004, *p < 0.02, **p < 0.006, *p < 0.01 and *p < 0.02 compared to control. The compounds screened and the concentrations used are shown on the *x*-axis.



Fig. 4 Effect of selected compounds on (A) HCT-116 and (B) MCF-7, colony formation. Bar graphs (A and B) both show the mean survival fraction of % control represented of mean \pm SD of five independent trials (n = 2 per trial). Significance is reported as *p < 0.05, **p < 0.005 compared to control.

compounds prevent (100%) colony formation at 10 μ M concentration. At 5 μ M between 5 and 50% inhibition of colony formation is seen. Fig. 3 also demonstrates compounds 3 suppress HCT-116 colony formation. Compound 3f was the most effective, completely inhibiting colony formation at both 5 and 10 μ M. At 10 μ M compounds 3a, 3q, 3t, 3a' and 3b' completely prevented colony formation while at 5 μ M only 5–30% inhibition was observed.

3.2.5 Cell cycle analysis. To shed light on the mechanism of action of this class of compound, **3f** was investigated as a representative example in the cell-cycle assay. After 24 h treatment of HCT-116 and MCF-7 with compound **3f** (5 and 10 μ M) both cell lines showed increases in the portion of cells in the G2/M phase (Fig. 5). The observed G2/M arrest indicates DNA damage and cell cycle checkpoint attempts to initiate repair. Pre-G1 events (5–8%) were detected in HCT-116 populations exposed to **3f**, an indication of caspase-excision of DNA characteristic of apoptosis. Consistent with this the MCF-7 cell line showed negligible pre-G1 cell populations; MCF-7 cells lack the caspase 3 proteases responsible for DNA excision and protein cleavage.²⁷ Here the G2/M (MCF-7) cell accumulation

also indicates DNA damage and attempt at repair. For HCT-116 the highest accumulation of cells in the G2/M phase at 5 and 10 μ M concentrations was 22% and 26% compared to control (14%). The G2/M phase arrest is somewhat more obvious in MCF-7 cells, with the maximum accumulation of events observed in G2/M phase at 5 and 10 μ M concentration being 23% and 28% compared to the control (11%). Our studies clearly showed that increase in agent **3f** concentration resulted in significant (p < 0.01) increase in G2/M.

3.2.6 Caspase activation. To confirm that compounds 3 cause apoptosis in HCT-116 and MCF-7 cells, the activation of caspases 3 and 7 was studied following exposure of cells (72 h) to 5 and 10 μ M 3b' and 3f (Fig. 6). Significant dose-dependent caspase activation was observed after 72 h exposure of the cells to these agents (Fig. 5) which is consistent with apoptosis-induction. These data suggest that 3b' and 3f exert their cytotoxic activity *via* induction of caspase-dependent apoptosis.

3.2.7 Western blot assay. Confirmation of apoptosisinduction by **3f** was further investigated by monitoring the expression levels of key apoptotic proteins. Poly (ADP-ribose) polymerase-1 (PARP-1) is a substrate of the caspase-3 protein,

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence Open Access Article. Published on 28 November 2022. Downloaded on 8/16/2025 12:42:14 PM. (cc)) BY-NC



Fig. 5 Cell-cycle histograms summarising the effect of **3f** on cell-cycle progression of HCT-116 (A) and MCF-7 (B) cells after 24 h of treatment at concentrations of 5 and 10 μ M concentrations; 20 000 events were counted. Number of internal repeats three times. Primary flow cytometry traces are given in the ESI.†



Fig. 6 Caspase-3/7 activity of HCT-116 (A) and MCF-7 (B) cells after 72 h of treatment with **3b**' and **3f** at concentrations of 5 and 10 μ M. Each experiment was repeated twice with five internal repeats. Bars and error bars refer to the mean \pm SD. **p* < 0.01 *vs.* control, ****p* < 0.0005 *vs.* control respectively.

present in HCT-116 cells and involved in a number of cellular processes. Its cleavage is indicative of apoptosis in HCT-116 cell lines.³⁰ Therefore, HCT-116 cells were treated with **3f** (5 and 10 μ M, 24 h). The results obtained (Fig. 7) demonstrate that **3f** induces concentration-dependent PARP-1 cleavage, accompanied by down-regulation of whole PARP, suggesting apoptosis induction. The presence of cleaved PARP is also indicative of caspase activation, consistent with the caspase 3/7 results above.



Fig. 7 Effect of compound 3f on expression of whole and cleaved PARP in HCT 116 cells. (A and B) Data are mean \pm SD of three independent experiments (ANOVA followed by Dunnett's test), significance is reported as *p < 0.05. (C) Representative western blots of HCT 116 lysates following treatment of cells with **3f** (5 and 10 μ M) are given. The data are the mean SD of three independent experiments (ANOVA followed by Dunnett's test). Significance is reported as: *p < 0.05.

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Open Access Article. Published on 28 November 2022. Downloaded on 8/16/2025 12:42:14 PM. BΥ-NC 00

4. Conclusions

A library of 30 novel 2-(2-benzylidenehydrazinyl)-4-(4cyanophenyl)thiazole derivatives (3a-d') were synthesised. These demonstrate potent and selective antitumour activity against two cell lines representative of colorectal (HCT-116) and breast (MCF-7) cancer phenotypes. Compound 3f ($R^3 = 2$ hydroxy-3-methylphenyl) was found to be the most general efficient growth inhibitor with GI_{50} value 1.0 \pm 0.4 μM against MCF-7. Compound 3n ($R^3 = 2,6$ -Cl₂C₆H₃) exhibited highest inhibition potential (GI₅₀ 1.1 \pm 0.5 μ M) against HCT-116. The selectivity of compounds towards the cancer cell lines over noncancer cells was estimated by equivalent exposure to MRC-5 (normal fibroblasts). Only one compound $3\mathbf{w}$ ($\mathbf{R}^3 = 2,4,6$ -C₆H₃F₃) was more active against MRC-5, while all other compounds were more active against the carcinoma cell lines (often appreciable so *e.g.* >5× for 3b', >10× for 3f). Cell cycle, caspase activation and western blot assays established that compounds $\mathbf{3b}'(\mathbf{R}^3 = 3$ -bromothiophene) and $\mathbf{3f}(\mathbf{R}^3 = 2$ -(OH)-3-MeC₆H₃) induce cancer cell death via caspase-dependent apoptosis and that these compounds are significantly more active than previously reported related thiazoles. It is too premature to speculate in depth on the exact mechanism of action of the compounds 3. However, we note that very recently a related group of thiazoles were described that are potent kinase inhibitors.40 It is possible that our own compounds operate similarly as preliminary experiments also showed ERK1/2 inhibition for 3f. In conclusion, these synthetically accessible molecules are worthy of further preclinical evaluation including further examination against broad-spectrum cancer phenotypes and elucidation of their mechanism of action.

Author contributions

Tashfeen Akhtar planned the synthesis. Hasnain Mehmood synthesized the compounds and carried out all spectral analysis. Mustapha Musa carried out all the biological assays. Simon Woodward led the writing of the manuscript. Tracey Bradshaw and Andrew Nortcliffe contributed in biological results analysis and interpretation. Shahdat Hossan assisted in biological assays. Muhammad Haroon provided critical review and feedback.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

HM is thankful to the Higher Education Commission (HEC) of Pakistan for a fellowship under the International Research Support Initiative (IRSIP) Program. MM is grateful to the University of Nottingham for the award of a Vice Chancellor's Scholarship for Research Excellence. We thank the referees for their valuable insights and suggestions for this paper.

References

- 1 *Green Approaches in Medicinal Chemistry for Sustainable Drug Design*, ed. B. Banik, Elsevier, Amsterdam, 2020, p. 1021.
- 2 M. Milanesi, A. Runfola and S. Guercini, *J. Clean. Prod.*, 2020, **261**, 121204.
- 3 M. Fridlender, Y. Kapulnik and H. Koltai, *Front. Plant Sci.*, 2015, **6**, 799.
- 4 P. C. Sharma, K. K. Bansal, A. Sharma, D. Sharma and A. Deep, *Eur. J. Med. Chem.*, 2020, **188**, 112016.
- 5 S. Jain, S. Pattnaik, K. Pathak, S. Kumar, D. Pathak, S. Jain and A. Vaidya, *Mini-Rev. Med. Chem.*, 2018, **18**, 640.
- 6 M. Abid, R. Nouch, T. D. Bradshaw, W. Lewis and S. Woodward, *Eur. J. Inorg. Chem.*, 2019, 2774.
- 7 D. Secci, S. Carradori, B. Bizzarri, A. Bolasco, P. Ballario, Z. Patramani, P. Fragapane, S. Vernarecci, C. Canzonetta and P. Filetici, *Bioorg. Med. Chem.*, 2014, 22, 1680.
- S. Carradori, D. Rotili, C. De Monte, A. Lenoci, M. D'Ascenzio, V. Rodriguez, P. Filetici, M. Miceli, A. Nebbioso and L. Altucci, *Eur. J. Med. Chem.*, 2014, **80**, 569.
- 9 K. Z. Łączkowski, M. Świtalska, A. Baranowska-Łączkowska, T. Plech, A. Paneth, K. Misiura, J. Wietrzyk, B. Czaplińska, A. Mrozek-Wilczkiewicz, K. Malarz, R. Musiol and I. Grela, *J. Mol. Struct.*, 2016, **1119**, 139.
- 10 F. S. A. Rahman, S. K. Yusufzai, H. Osman and D. Mohamad, J. Phys. Sci., 2016, 27, 77.
- 11 K. Vaarla, R. K. Kesharwani, K. Santosh, R. R. Vedula, S. Kotamraju and M. K. Toopurani, *Bioorg. Med. Chem. Lett.*, 2015, 25, 5797.
- 12 T. I. de Santana, M. de Oliveira Barbosa, P. A. T. de Moraes Gomes, A. C. N. da Cruz, T. G. da Silva and A. C. L. Leite, *Eur. J. Med. Chem.*, 2018, **144**, 874.
- 13 Y. Wang, C. Wu, Q. Zhang, Y. Shan, W. Gu and S. Wang, *Bioorg. Chem.*, 2019, **84**, 468.
- R. Raveesha, A. Anusuya, A. Raghu, K. Y. Kumar, M. D. Kumar, S. B. Prasad and M. Prashanth, *Comput. Toxicol.*, 2022, 21, 100202.
- 15 A. Rauf, M. K. Kashif, B. A. Saeed, N. A. Al-Masoudi and S. Hameed, *J. Mol. Struct.*, 2019, **1198**, 126866.
- 16 M. C. Al-Matarneh, R.-M. Amărandi, I. I. Mangalagiu and R. Danac, *Molecules*, 2021, **26**, 2066.
- 17 H. Mehmood, M. Haroon, T. Akhtar, S. Woodward and H. Andleeb, *J. Mol. Struct.*, 2022, **1250**, 131807.
- 18 S. Bargujar, S. Chandra, R. Chauhan, H. K. Rajor and J. Bhardwaj, *Appl. Organomet. Chem.*, 2018, **32**, e4149.
- 19 M. T. Scotti, L. Scotti, H. M. Ishiki, L. M. Peron, L. de Rezende and A. T. do Amaral, *Chemom. Intell. Lab. Syst.*, 2016, **154**, 137.
- 20 G. Springett, S. M. Sebti and N. J. Lawrence, PCT Patent, WO2015157242A1, 2015, p. 55.
- 21 H. Hammoud, K. Elhabazi, R. E. Quillet, I. Bertin, V. Utard, E. Laboureyras, J.-J. Bourguignon, F. Bihel, G. Simonnet and F. Simonin, ACS Chem. Neurosci., 2018, 9, 2599.
- 22 A. D. Khalaji, K. Fejfarova and M. Dusek, *J. Cryst. Miner.*, 2013, **19**, 1.

- 23 B. Donarska, M. Świtalska, W. Płaziński, J. Wietrzyk and K. Z. Łączkowski, *Bioorg. Chem.*, 2021, **110**, 104819.
- 24 B. N. Sağlık, D. Osmaniye, S. Levent, U. A. Çevik,
 B. K. Çavuşoğlu, Y. Özkay and Z. A. Kaplancıklı, *Eur. J. Med. Chem.*, 2021, 209, 112918.
- 25 A. Mignot, M. Miocque, P. Binet, J. Rapin, P. Rinjard, M. Roux, M. Cals and J. Ekindjian, *Eur. J. Med. Chem.*, 1980, **15**, 33.
- 26 T. Mosmann, J. Immunol. Methods, 1983, 65, 55.
- 27 I. Nicoletti, G. Migliorati, M. Pagliacci, F. Grignani and C. Riccardi, *J. Immunol. Methods*, 1991, **139**, 271.
- 28 M. K. B. Break, M. S. Hossan, Y. Khoo, M. E. Qazzaz, M. Z. Al-Hayali, S. C. Chow, C. Wiart, T. D. Bradshaw, H. Collins and T.-J. Khoo, *Fitoterapia*, 2018, **125**, 161.
- 29 E. Harlow and D. Lane, Cold Spring Harbor Protocols, 2006, 2006, DOI: 10.1101/pdb.prot4283.
- 30 T. Mahmood and P.-C. Yang, N. Am. J. Med. Sci., 2012, 4, 429.
- 31 V. Fadeeva, V. Tikhova and O. Nikulicheva, J. Anal. Chem., 2008, 63, 1094.

- 32 M. Haroon, T. Akhtar, M. Yousuf, M. N. Tahir, L. Rasheed, S. S. Zahra and M. Ashfaq, *BMC Chem.*, 2022, 16, 1.
- 33 H. Mehmood, M. Khalid, M. Haroon, T. Akhtar, M. Ashfaq, M. N. Tahir, M. U. Khan, M. Imran, A. A. C. Braga and S. Woodward, *J. Mol. Struct.*, 2021, **1245**, 131043.
- 34 M. J. Waring, Expert Opin. Drug Discovery, 2010, 5, 235.
- 35 C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, *Adv. Drug Delivery Rev.*, 2001, **46**, 3.
- 36 D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, *J. Med. Chem.*, 2002, 45, 2615.
- 37 P. D. Leeson and B. Springthorpe, *Nat. Rev. Drug Discovery*, 2007, **6**, 881.
- 38 Molinspiration Cheminformatics free web services, https:// www.molinspiration.com, Slovensky Grob, Slovakia.
- 39 T. Sander, J. Freyss, M. von Korff and C. Rufener, *J. Chem. Inf. Model.*, 2015, 55, 460.
- 40 A. Y. Khormi, T. A. Farghaly, A. Bayazeed, Y. O. Al-Ghamdi, H. G. Adulwahab and M. R. Shaaban, *RSC Adv.*, 2022, **12**, 27355.